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Despite years of research, post-spinal cord injury (SCI) chronic neuropathic pain remains 
refractory to treatment and drastically impairs quality of life for SCI victims beyond 
paralysis.  Although inflammation and free radicals contribute to neuropathic pain in SCI, 
the mechanism is not completely clear. We have recently demonstrated that acrolein, a 
product and catalyst of lipid peroxidation, induces a vicious cycle of oxidative stress, 
amplifying its effects and perpetuating oxidative stress and inflammation.  In the current 
study, we have confirmed that acrolein is elevated significantly at least two weeks post-
SCI which coincides with the emergence of hyperalgesia (mechanical, cold and 
thermal).  Furthermore, anti-acrolein treatment hydalazine can reverse pain behavior. 
Consistent with this, acrolein is a known ligand that directly excites transient receptor 
potential ankyrin 1 receptor (TRPA1) in DRG nociceptive neurons to transmit pain 
sensation. In addition, we have observed a significant increase of monocyte 
chemoattractant protein-1 (MCP1), a pro-inflammatory chemokine that is also known be 
increased upon acrolein stimulation and capable of sensitizing TRPA1 following SCI. 
Similarly, we observed a heightened excitatory response of DRG sensory neurons to 
current stimulation in the presence of acrolein, indicating an enhanced sensitivity of DRG 
cells to acrolein post SCI. In summary, acrolein may play an important role in the post 
SCI hyperalgesia through greater direct binding to TRPA1 and enhanced sensitivity of 




CHAPTER 1. INTRODUCTION 
1.1 Introduction of Spinal Cord Injury 
 
According to the National Spinal Cord Injury Statistical Center, there are 
approximately 400,000 spinal cord injured patients in the United States with over 14,000 
new injuries occurring each year. Traumatic spinal cord injury (SCI) could result in 
irreversible never injury which leads to both motor and sensory malfunction. In addition 
to the motor and sensory dysfunction, SCI patients can also suffer from various levels of 
neuropathic pain, bladder reflexive dysfunction, urinary tract infection, renal malfunction, 
loss of respiratory function, loss of sexual function, pneumonia, deep vein thrombosis, 
pulmonary embolism, and septicemia. These SCI-induced disorders have significantly 
negative effects on their quality of life. In addition, SCI results in significant financial 
impact. Based on data from the National Spinal Cord Injury Statistical Center, the 
estimated lifetime costs for a 25 years old tetraplegia patient is over $3 millions.  
 
Despite years of study to improve the functional recovery and the quality of life, 
lack of effective therapeutic targets result in a frustrating condition to treat. High doses of 
methylprednisolone have been using as a standard care for SCI clinical trials because of 
its antioxidant properties (Bracken et al., 1997; Bracken et al., 1998; Bracken and 
Holford, 2002). However, recent clinical trials have failed to improve functional recovery 
after SCI with methylprednisolone treatment. Based on research, this treatment could 
lead to respiratory tract infection, urinary tract infection, pulmonary embolism, and 
gastrointestinal problems (George, 1995; Matsumoto et al., 2001; Lee et al., 2007; 
Suberviola et al., 2008b). Even though treatment with methylprednisolone may not be 
effect way to improve SCI patients’ symptoms, these clinical applications demonstrated 
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that attenuating oxidative stress, as a one of the therapeutic strategies, could be a effective 
way to improve the motor and sensory dysfunction following SCI.  
 
1.2 The Role of Oxidative Stress after SCI    
 
One of the critical features of SCI pathophysiology is the secondary cascade events 
after primary traumatic SCI, which occur in the hours, days, and weeks including 
ischemia/reperfusion injury, inflammation, oxidative stress, and glutamate excitotoxicity 
(Braughler and Hall, 1989b; Juurlink and Paterson, 1998b; Hall and Springer, 2004). The 
secondary cascade events result in spreading of additional damage throughout the spinal 
cord and contributing to the tissue degeneration and functional loss (Hall and Springer, 
2004; Huang and Huang, 2006).  
 
As a key factor of secondary cascade events, oxidative stress plays a critical role in 
mediating motor and sensory dysfunction after SCI. In addition, oxidative stress has been 
implicated in various neurodegenerative diseases (Hall, 1989; Hall and Braughler, 1993a; 
Smith et al., 1999; Seiler, 2000). Traumatic mechanical SCI injury to the membrane 
induces the disruption the intracellular calcium and sodium rise, and potassium falls 
which contribute to depolarization leading to intracellular level of calcium and sodium 
increase more. Furthermore, increase level of calcium could result in mitochondria injury 
and an increase in production and release of reactive oxygen species (ROS) (Hall, 1996; 
Xiong et al., 2007).  
 
Traumatic primary SCI induces blood supply disruption which results in ischemia-
reperfusion secondary injury. Shortage of oxygen and glucose may lead to impaired ATP 
production, mitochondrial damage, and generation and leakage of ROS from 
mitochondria (Braughler and Hall, 1989a; Hall and Braughler, 1993b). The generation of 
xanthine oxidase has been found to produce superoxide after ischemia-reperfusion 
damage (Braughler and Hall, 1989a; Hall, 1996; Juurlink and Paterson, 1998a; Kumar et 
al., 2004). In addition, recruitment of neutrophils to the tissue damage site and their 
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activations results in the increase in generation of ROS (Braughler and Hall, 1989a; 
Lewen et al., 2000).  
 
The central nerve system (CNS) is especially very sensitive to oxidative stress 
because of its unique properties. Particularly, the CNS, compared to the other tissue, 
contains large proportion of phospholipids membrane and poly unsaturated fatty acids, 
which are specifically vulnerable to peroxidation (Hall and Braughler, 1993b; Hall, 1996; 
Halliwell and Gutteridge, 1999). Furthermore, compared to other types of cells, there are 
a number of mitochondria that could be a target and source of ROS. Under the high level 
of oxidative stress, the endogenous antioxidants such as glutathione, vitamin E, and 
ascorbic acid could be overwhelmed because the level of antioxidants may not be 
compensated due to rapid consumption. Even though many of research groups have been 
demonstrated that oxidative stress plays an important role in the pathogenesis after SCI, 
clinical trials with free radical scavengers have failed to promote functional recovery 
after traumatic SCI (George et al., 1995; Bracken et al., 1997; Bracken et al., 1998; 
Suberviola et al., 2008a). Therefore, we need to understand the mechanisms of oxidative 
stress and investigate the novel and effective therapeutic targets for SCI.  
 
In addition to SCI, many of byproducts of oxidative stress have been implicated in 
numerous neurodegenerative diseases (Liu and Ji; Yowtak et al.; Hensley et al., 2000; 
Vincent et al., 2002; Naoi et al., 2005; Schwartz et al., 2008). The research for 
byproducts of oxidative stress-mediated neuronal diseases has been an intense area to 
prevent and slow down the development of various neurodegenerative diseases. However, 
clinical trials with free radical scavengers have not produced meaningful outcome similar 
to SCI. In this sense, this study could have critical applications for not only SCI patients 






1.3 The Origin of Acrolein and Role of Acrolein in Spinal Cord Injury 
 
Acrolein is a highly reactive α,β-unsaturated aldehyde (Figure 1.) that is an 
environmental pollutant and byproduct of lipid peroxidation (LPO) after traumatic injury 
to spinal cord (Uchida, 1999a; Lovell et al., 2000; O'Brien et al., 2005). Acrolein can 
originate via endogenous pathway from LPO of poly unsaturated fatty acid in cell 
membrane, carbohydrates and amino acids. In addition, generation of acrolein occurs 
through exogenously such as incomplete combustion of organics, manufacturing 
processes, and cigarette smoke (Witz, 1989; Esterbauer et al., 1991a; Ghilarducci and 












In addition, because acrolein can act as byproducts and inducers of LPO, it has 
been implicated in many neurological diseases (Shi et al.; Horton et al., 1999; Lovell et 
al., 2000; Waxman, 2001; Luo and Shi, 2004; Luo et al., 2005a; Liu-Snyder et al., 2006b; 
Due et al., 2014). Acrolein has been shown to be the most reactive and abundant 
electrophile byproducts of LPO compared to much studied ROS. In addition, it can 
directly bind to proteins, DNA, and endogenous antioxidant glutathione (GSH) and reacts 
with GSH 100-150 times faster than another type of LPO byproducts such as 4-
hydroxynonenal (4-HNE) (Witz, 1989; Esterbauer et al., 1991a; Hall and Braughler, 
1993b; Ghilarducci and Tjeerdema, 1995; Uchida et al., 1998; Halliwell and Gutteridge, 
1999; Uchida, 1999b). Furthermore, half life of acrolein is significantly longer than that 
of other transient ROS. Acrolein-protein and acrolein-GSH adducts also have much 
longer half-lives than those of free acrolein and significantly reactive (Adams and 
Klaidman, 1993; Burcham et al., 2004; Kaminskas et al., 2004b). In addition, acrolein 
can react with the thiol group of cysteine residue, the ε-amino group of lysine and 
histidine residues to generate reactive carbonyl-retaining adducts through the Michael 
addition (Esterbauer et al., 1991a; Burcham et al., 2004; Kaminskas et al., 2004a; 
Burcham and Pyke, 2006). Particularly, binding between acrolein and cystein via Michael 
addition is reversible so that acrolein can break from acrolein-cystein adduct and allow it 
to continue to react with other proteins. Acrolein can also bind to necleophilic DNA 
bases to generate exocyclic adducts (Kehrer and Biswal, 2000a). Through this pathway, 
acrolein can induce vicious cycle of oxidative stress and amplify its effect to many 
















Figure2. Vicious Cycle of Oxidative Stress by Acrolein after Traumatic SCI. 
 
1.4 Acrolein Detection Techniques  
 
Because of reactive and volatility nature of acrolein, the detection of free acrolein is 
technically challenging. In addition, acrolein is able to undergo spontaneous 
polymerization, reduction, and oxidation because there are carbonyl and vinyl functional 
groups on the molecule (Shi et al., 2011). In this sense, based on the current researches 
and understating of characteristics of acrolein, it is reasonable to anticipate that majority 
of endogenous acrolein would exist in acrolein-protein adducts or be metabolized by 
endogenous antioxidants such as GSH and vitamin E.  
 
Detecting acrolein-lysine adduct level by using immunoblotting methods has been 
using in many rat SCI model (Uchida, 1999a; Hamann et al., 2008b; Hamann and Shi, 
2009; Park et al., 2013) (Figure 3). By using these techniques, many researchers could 
quantify the in vivo acrolein adducts level directly at the tissue of interest. In addition, 
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with the acrolein standard, actual in vivo acrolein level could be estimated. Although 
immunoblotting methods are very sensitive for in vivo acrolein level detection, using 
anti-acrolein antibodies to detect acrolein-lysine adduct only represent a portion of the 
total generated acrolein, which could always underestimate the actual acrolein level in the 
tissue. In addition, acrolein normally reacts with endogenous antioxidant GSH first, 
which results in a relative small amount of acrolein would bind to protein in normal 
condition of cell. Under this condition, immunoblotting methods could overlook the in 
vivo level of acrolein. Lastly, these methods are highly invasive because animals should 
be sacrificed to collect tissues which significantly limit their applications for the clinical 
trial. Therefore, a non-invasive method for detecting acrolein or acrolein metabolites 
would be effective for the investigation of acrolein-mediated neurodegenerative diseases 


























Figure 3. Detection of Acrolein-lysine Level through Immunoblotting Method. 
Top: artificially acrolein standard were prepared with different concentrations of acroelin. 
The monoclonal anti-acrolein antibody was used for acrolein standard samples. Bottom: 
based on the optical density of prepared acrolein samples, sample standard curve was 






Non-invasive acrolein level measurement through acrolein metabolite in urine 
quantification has been reported (Zheng et al.; Lovell et al., 2001b; Abraham et al., 2011; 
Zheng et al., 2013) (Figure 4). Rather than invasive acrolein measuring via 
immunoblotting, this method was considered to be an indirect indicator of the in vivo 
acrolein level. In addition, detecting acrolein metabolite through collecting urine makes it 
particularly promise for the clinical applications. Specifically, 3-hydroxypropyl 
mercapturic acid (3-HPMA) has been selected as a major acrolein metabolite in urine 
(Park et al., 2000; Yan et al., 2010). Chemically, 3-HPMA is very stable and be kept for 
months in the freezer without sample deterioration. Furthermore, binding ratio between 
acrolein and GSH is 1:1, which indicates that 3-HPMA is a suitable biomarker to 
quantify the in vivo level of acrolein after SCI or acrolein-mediated neurodegenerative 
diseases (Schettgen et al., 2008; Yan et al., 2010; Park et al., 2013). The acrolein 
metabolite 3-HPMA in urine could be detected via liquid chropatography (LC) and mass 



























Figure 4. Detection of 3-HPMA Level through LC/MS/MS Method 
The reaction scheme between acrolein and endogenous antioxidant GSH (A). The result 
of LC/MS/MS of acrolein metabolite 3-HPMA level detection. d3-3-HPMA was used as 












However, there are difference acrolein levels between 3-HPMA measuring and 
immunoblotting acrolein-lysine adduct levels (Park et al., 2013; Zheng et al., 2013). 
These discrepancies between two results could be explained through first, limited 
diffusion characteristics of acrolein into the blood stream. Second, immunoblotting is 
tissue and local specific, but 3-HPMA urine level was detected via systemically; this 
increased level cannot be considered to be a specific tissue. So, using these two different 
methods could contribute to a more precise detection level of acrolein following SCI.  
 
1.5 Acrolein Scavenging  
 
Because acrolein plays a critical role in secondary cascade events after traumatic 
primary SCI, acrolein scavenging would be an effective method to investigate the role of 
acrolein in SCI and other neurodegenerative diseases, and to improve motor and sensory 
dysfunction after SCI.  
 
Anti-hypertensive medication hydralazine, which is the FDA approved drug, has 
been shown to its acrolein scavenging properties (Burcham et al., 2000; Burcham et al., 
2002; Burcham et al., 2004). Hydralazine is a strong nucleophile and it has a hydrazide 
functional group. Through hydrazide group, hydralazine can bind to and neutralize 
acrolein and acrolein-protein adducts (Burcham et al., 2004; Kaminskas et al., 2004a, b; 
Burcham and Pyke, 2006) (structure and reactions between hyalazine and free acrolein 
shown in figure 5). Hydralazine reacts with free acrolein and acrolein-protein adduct in 
an equimolar manner to neutralize in a cell free system, so equimolar concentration of 
hydralazine could eliminate nearly whole acrolein (Zhu et al.; Burcham et al., 2000; 

































The reaction products between hydralazine and acrolein were identified as (1E)-
acrylaldehyde phthalazin-1-ylhydrazone (E-APH) and (1Z)-acrylaldehyde phthalazin-1-
ylhydrazone (Z-APH)(Zhu et al., 2011). E-APH is the primary reaction product, which 
can significantly attenuate the acrolein-induced cellular toxicity and be excreted from 
body safely.  
 
Based on previous studies, hydralazine can prevent acrolein-induced PC-12 cells’ 
death and injuries (Liu-Snyder et al., 2006a; Liu-Snyder et al., 2006b). In addition, 
hydralazine also prevents acrolein-mediated allyl alcohol-induced hepatotoxicity in in 
vitro hepatocytes (Burcham et al., 2000; Burcham et al., 2004). In addition, hydralazine 
can reduce the acrolein-mediated membrane damage, oxidative stress, and loss of 
compound action potential (Hamann et al., 2008a; Hamann and Shi, 2009). Furthermore, 
the isolated spinal cord ex vivo study showed that hydralazine can alleviate compression-
induced the level of acrolein and acrolein-protein adducts in spinal cord (Hamann et al., 
2008a). 
 
Recent research has demonstrated that hydralazine could reach therapeutic 
concentration in 2 hours by systemic injection (Wang et al., 2011). The data has 
demonstrated that the level of hydralazine in spinal cord, brain and kidney were higher 
than minimum level of hydralazine which could alleviate the acrolein-mediated cellular 
death. Because a specific gravity value of spinal cord tissue is 1, the hydralazine level in 
the spinal cord can be calculated about 20 μmol/L which is in the range of therapeutic 
concentrations, 25 μmol/L (Liu-Snyder et al., 2006a). In addition, compared to 
bioavailability of oral application, which is about 40%, bioavailability through systemic 
application is about 90% (Hamann et al., 2008a). Taken all together, these results 
supported that systemic application of hydralazine may be an effective treatment for 
traumatic SCI and acrolein-induced neurodegenerative diseases via scavenging acrolein.  
 
One of limitations of hydralazine is its hypertensive effect. Especially, 
vasodilatory effect by hydralazine could be life threatening side effect to SCI patients, as 
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they would be get neurogenic shock (Tuncel and Ram, 2003). Short half life of 
hydralazine is also another limitation for clinical application of hydralazine. Based on 
previous study, half life of hydralazine in vivo is only about 1 hour to 2 hours (Reece, 
1981), which is significantly shorter than expected oxidative stress and acrolein 
production time window after SCI. However, many of in vitro studies using hydralazine 
have demonstrated that acrolein scavenging is an effective ways for intervention to 
oxidative stress. Because the hydrazine functional group is in charge of scavenging the 
acrolein, developing or investigating an alternative acrolein scavengers without 
antihypertensive effect would be needed. 
 
 There are other molecules that have a hydrazine functional group like hydralazine. 
Their chemical structure can be seen in figure 6. Phenelzine has a hydrazine functional 
group which can react with acrolein equimolar manner like hydralazine (Wood et al., 
2006a). In addition, phenelzine is not a vasodilator so it can be used at higher doses than 
hydralazine safely and as an alternative to hydralazine. Furthermore, its half life is much 
longer than that of hydralazine so it can provide additional neuro-protection effect after 
SCI (Shi et al., 2011; Zheng et al., 2013). Even though phenelzine is the FDA approved 
anti-depressant, the safety of phenelzine as an acrolein scavenger for clinical application 
should be established through further research. Another possible acrolein scavenger is 
dihydralazine which has two hydrazine functional groups. Therefore, it could potentially 
be twice as efficient as hydralazine’s acrolein scavenging (Kaminskas et al., 2004a). 
Dihydralazine has been shown to alleviate the acrolein level in a cell-free system and also 
prevent acrolein-induced release of lactate dehydrogenase (LDH) in in vitro hepatocytes 
study (Kaminskas et al., 2004b). Taken together, although phenelzine and dihydralazine 
can be considered as an acrolein scavenger alternative to hydralazine, researches for their 


















Figure 6. Chemical Structure of Acrolein Scavengers 















1.6 Classification of Pain 
 
1.6.1 Nociceptive Pain 
Nociceptive pain is an early-warning physiological alarm system which is 
mediated by high-threshold unmyelinated C or thinly myelinated Aδ primary sensory 
neurons (Woolf, 2007; Woolf and Ma, 2007). This is the normal sensory reaction when 
we sense noxious stimulus such as something too hot, cold, or sharp. Only the intense 
stimuli (noxious stimuli) that are higher than threshold can activate nociceptive sensory 
neuron (Basbaum et al., 2009) and once the noxious stimuli are disappeared, the 
nociceptive pain would also be removed. Nociceptive sensory neurons express specific 
transducers, mainly transient receptor potential (TRP) channels on C or/and Aδ primary 
sensory, which can transmit noxious stimuli into electrical activity (Clapham, 2003; Tai 
et al., 2008). 
 
1.6.2 Inflammatory Pain 
Inflammatory pain is responsible for responding to tissue damage and the 
subsequent immune reaction. This pain is also protective like nociceptive pain in order to 
aid healing and repair of the damaged tissues by creating the hypersensitivity to avoid 
physical contact and movement (Sandhir et al.; Marchand et al., 2005; Lucas et al., 2006). 
Under this condition, normally non-painful factors become painful factors (allodynia) so, 
response to normal stimuli and noxious stimuli are exaggerated and lasted (Marchand et 
al., 2005; Lucas et al., 2006). In addition, damaged tissues and immune reaction to 
infection can result in release of various chemical mediators which create an 
inflammatory soup (histamine, serotonin, ATP and bradykinin) (Gilden, 2005; Marchand 
et al., 2005; Moalem and Tracey, 2006; Ren and Dubner, 2008). These inflammatory 
soups can activate and modify the responsiveness of nociceptor afferents to stimuli 





1.6.3 Neuropathic Pain 
Neuropathic pain is not adaptive and protective, but maladaptive which results 
from both lesion and diseases to the central nervous system (CNS). In addition, 
neuropathic pain can result in both neurological disorders and pain (Scholz and Woolf, 
2007). Under this condition, nociceptive pathway could be changed by peripheral 
sensitization and central sensitization so that normally non-painful factors produce the 
pain (allodynia) and response to noxious stimuli could be enhanced (hyperalgesia) 
(Zimmermann, 2001; Campbell and Meyer, 2006; Costigan et al., 2009a). Peripheral 
sensitization indicates that a reduction in threshold and an increase in sensitivity at the 
nociceptor in peripheral terminal ending. It can result in the pain hypersensitivity at the 
tissue damage and inflammation (Zhuo, 2007; Costigan et al., 2009a). Central 
sensitization is an increase in the excitability of sensory neuron in the CNS, which results 
from damage or/and diseases. Under the central sensitization, normal sensory information 
begins to generate abnormal responses so, low-threshold primary afferent sensory 
neurons which are activated by innoxious stimuli can activate neurons in the spinal cord 
and/or the brainstem that normally respond to only noxious stimuli (Zimmermann, 2001; 
Zhuo, 2007; Costigan et al., 2009a). In addition, after damage to the CNS, the immune 
cells are activated in the CNS, which increase the release of cytokines and also lead to 
central sensitization (Costigan et al., 2009b; White et al., 2009).  
 
1.7 Chronic Neuropathic Pain after Traumatic Spinal Cord Injury 
 
Chronic neuropathic pain is commonly found in SCI patients. Based on the 
previous studies, traumatic SCI could lead to a chronic neuropathic pain within months 
(Richards et al., 1980) and more than 80% of SCI patients suffer from significant pain 
which is felt as burning and stabbing (Siddall et al., 2003). As a matter of fact, beyond 
paralysis, chronic neuropathic pain further drastically impairs the quality of life for SCI 
victims. Despite years of research, this type of clinical pain remains refractory to 
treatment. As a result, chronic neuropathic pain could be prolonged for several decades 
after SCI and leads to depression and suicide (Segatore, 1994; Cairns et al., 1996). There 
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are several possible mechanisms that can explain the generation of chronic neuropathic 
pain after SCI (Scholz and Woolf, 2002; Basbaum et al., 2009; Costigan et al., 2009a; 
Milligan and Watkins, 2009).  
 
First, after neuronal damage, the central terminal of non-nociceptive primary 
afferents Aβ fibers could make new synaptical connections with nociceptive neurons in 
laminae I and II. This re-connection and sprouting in the nociceptive pathway can result 
in persistent pain hypersensitivity 
 
Second, changing in glutamatergic neuron and N-methyl-D-aspartate (NMDA) 
receptor mediated sensitization. Under the normal condition, pain is transmitted by 
release of glutamate from the central ending of nociceptor neurons, which is generating 
excitatory postsynaptic currents (EPSCs) in secondary order neuron in the spinal cord 
dorsal horn interneurons. However, under the neuropathic pain condition, increased 
release of glutamatergic neurotransmitter from central ending of nociceptors would 
sufficiently depolarize and activate postsynaptic NMDA receptors. As a result, an 
increased in calcium influx can activate calcium-dependent signaling transductions such 
as MAPK, PKC and PI3K, which could keep activating the dorsal horn pain transmission 
resulting in exacerbating sensitivity to noxious stimuli.  
 
Third, after neuronal damage, the loss of function of GABAergic and/or glycinergic 
inhibitory interneurons could result in increased sensitivity. Under normal physiological 
condition, inhibitory interneurons continuously release inhibitory neurotransmitters such 
as Gamma-aminobutyric acid (GABA) and/or glycine to alleviate the excitability of 
lamina I interneurons and modulate pain transmission. However, under the setting of 
neuropathic pain physiology condition, there are loss of inhibitory effects (disinhibition), 
which contribute to the generation of allodynia and hyperalgesia. Disinhibition can make 
non-nociceptive myelinated Aβ primary afferent to involve in pain transmission circuitry, 




Lastly, glial cells such as microglia and astrocytes also can lead to chronic 
neuropathic pain after SCI. Under normal conditions, microglias act as resident 
microphages in the CNS. After injury within hours, microglias accumulate in the 
superficial dorsal horn and they release various cytokines and chemokines which can 
induce the central sensitization and persistent pain. However, in contrast to microglia, an 
activation of astrocyte is normally delayed and prolonged up to several months, which 
indicate that astrocytes may play an important role for the maintenance of persistent pain 
and induction of central sensitization after SCI. 
 
1.8 The Role of Reactive Oxygen Species in Neuropathic Pain 
 
Recent studies have shown that ROS are also implicated in neuroapthic pain 
(Yowtak et al.; Kim et al., 2004; Park et al., 2006; Gao et al., 2007). Kim et al showed 
that the nerve ligation induced-neuropathic pain allodynia significantly reversed after 
treatment with various ROS scavengers (Kim et al., 2004; Kim et al., 2006). This data has 
demonstrated that ROS could play a critical role in the maintenance of neuropathic pain. 
As we already discussed about the role of NMDA receptors in central sensitization after 
SCI, an increased in the phosphorylation of NMDA receptor in the spinal dorsal horn is a 
one of the key factors for inducing the neuropathic pain and central sensitization. In 
addition, previous study has showed that oxidative stress in the spinal cord also 
contributed to maintaining a high level of phosphorylation of NMDA receptors in dorsal 
horn which results in central sensitization. Furthermore, elevated levels of ROS in the 
spinal cord can activate various protein kinases such as PKA and PKC, which again 
elevate the level of phosphorylation of NMDA receptor. In addition, Gao et al have 
demonstrated that the level of activated NMDA receptors in the dorsal horn and 
neuropathic pain behaviors were significantly attenuated by systemic application of ROS 
scavenger in neuropathic pain animal model (Gao et al., 2007). These studies indicate 
that ROS are implicated in phosphorylation of NMDA receptor which results in 
neuropathic pain behavior after SCI, and ROS scavengers can be used as analgesic by 
blocking ROS-related signaling pathways after SCI.  
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Again, another important mechanism that induces the chronic neuropathic pain was 
loss of inhibitory function after neuronal damage (in section 1.7). Several recent studies 
have demonstrated a sensitivity of GABA neurons to oxidative stress. Virgili et al 
showed that an antioxidant resveratrol, which was found in red wine could promote 
neuroprotective effect in vivo because it could selectively alleviate the reduction in 
GABA synthesizing enzyme levels in rat (Virgili and Contestabile, 2000). In addition, 
Chen et al have demonstrated that superoxide, which is a type of ROS, could lead to 
presynaptic inhibition of GABA release to postsynaptic neuron (Chen and Pan, 2007). 
This study indicated the vulnerability of GABA neuron to oxidative stress. One recent 
study showed that increase levels of spinal ROS can promote neuropathic pain behaviors 
such as mechanical hyperalgesia in normal mice, which was very similar to the pain 
behaviors in peripheral nerve injury-induced neuropathic pain animal model. In addition, 
they showed that ROS were critically involved in reducing presynaptic inhibitory GABA 
neurotransmitter release in neuropathic pain animal model. However, when they treated 
them with ROS scavengers, ROS-mediated effects were reversed. These data indicate 
that ROS promote the pathogenesis of neuropathic pain following SCI by interfering with 
the inhibitory function of the spinal GABAergic system, and ROS scavengers could 
effectively attenuate neuropathic pain behaviors, which are achieved through the restore 
of GABA-mediated inhibitory system. Furthermore, many of byproducts of oxidative 
stress could activate TRP channels on the nociceptive sensory neuron, which transmit the 
pain signaling to the CNS (Bautista et al., 2006). We will discuss about this in sections 
1.9 and 1.10 more specifically.  
 
1.9 Acrolein-mediated Sensory Dysfunction after SCI 
 
Although many of studies have demonstrated the role of ROS in neuropathic pain 
following SCI (Kim et al., 2004; Chen and Pan, 2007; Gao et al., 2007; Yowtak et al., 
2011), There are a few studies about acrolein and acrolein-protein adduct-mediated 
neuropathic pain after SCI. As a self-regenerative molecule, acrolein can generate 
additional acrolein and promote oxidative stress even with micro-molar levels of acrolein, 
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which indicate that acrolein may promote pathogenesis of neuropathic pain through 
oxidative stress after SCI (Luo and Shi, 2004).  
 
Many studies have shown that acrolein, is a neuropathic pain inducer after SCI 
through the transient receptor potential ankyrin 1 (TRPA1) (Bautista et al., 2006; Nilius 
et al., 2007; Andersson et al., 2008; Bessac et al., 2008). Specifically, TRPA1 channel act 
as sensor for byproducts of oxidative stress-derived molecules and of metabolisms. As a 
TRPA1 agonist, acrolein can bind to TRPA1 directly and activate TRPA1 channel 
(Bautista et al., 2006). Based on previous studies, gene expression level of TRPA1 is 
increased in the spinal dorsal horn and dorsal root ganglia (DRG) after SCI 
(Venkatachalam and Montell, 2007; Due et al., 2014).  
 
Due et al. have demonstrated that mechanical and cold allodynia could be observed 
in 2 weeks after SCI and lasted several weeks (Due et al., 2014). Also, data have shown 
that there was increased in expression level of acrolein at least 2 weeks after SCI, which 
was in coincidence with neuropathic pain mechanical and cold allodynia (Due et al., 2014; 
Park et al., 2014). Furthermore, Due and colleagues have shown that expression of 
TRPA1 messenger RNA (mRNA) level was increased seven days after SCI using lumbar 
level of DRG cells, which indicated that acrolein could contribute to generation of 
neuropathic pain even its level returned to normal physiological concentration after SCI. 
Furthermore, acrolein also acts as pro-inflammatory factor so that they can stimulate the 
release of chemokines after neuronal damage (Boddeke, 2001; Kirkham et al., 2003; 
Hulsebosch et al., 2009). Previous study has also shown that chemokine which was 
produced by pro-inflammatory factors such as acrolein could activate TRPA1 channel 
(Jung et al., 2008). In this sense, acrolein, both as a TRPA1 agonist and as a pro-
inflammatory factor, it can activate TRPA1 channel directly and indirectly through 
chemokine-medicated signaling pathways. 
 
An incidence of spontaneous activity and an increase in overall excitability state of 
DRG sensory neuron also are responsible for emergence and maintenance of neuropathic 
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pain after SCI other than acrolein level increase (Due et al., 2014). In this study, the data 
indicated that there was a decrease in the current threshold, which is minimum current to 
generate single action potential, in small and medium diameter of sensory neuron after 
SCI. In addition, there was an increase in number of DRG cells that responded to acrolein 
following SCI. Furthermore, acrolein could increase the excitability of sensory neuron at 
single DRG cell level, and acrolein-mediated sensory excitability was greater in the SCI 
group compared to the sham injury control group. The effect of acrolein in increase of 
sensory neuron’s excitability was further supported by Park and colleagues’ data. They 
have shown that exogenous injected acrolein into the spinal cord could promote not only 
the mechanical allodynia, but motor function and neuronal tissue deficits (Park et al., 
2014). Taken results of electrophysiology and in vivo acrolein injection together, acrolein 
can be considered as an endogenous pro-nociceptive factor after SCI.  
 
Based on current understanding and results from research, acrolein could be an 
effective therapeutic target as a pro-nociceptive and pro-inflammatory factor. The 
involvement of acrolein in chronic neuropathic pain after SCI was further demonstrated 
using acrolein scavenger hydralazine studies (Due et al., 2014; Park et al., 2014). The 
data showed that systemic application of hydralazine significantly attenuated mechanical 
and cold allodynia after SCI. The benefits of hydralazine as an analgesic lasted for 
several weeks and even worked two weeks delayed hydralazine application. This data 
indicated that acrolein scavenger hydralazine could prevent acrolein binding to TRPA1 
channel and alleviate the acrolein-mediated inflammatory events after SCI.  
 
These recent studies have demonstrated that acrolein could be a key therapeutic 
target in the generation of neuropathic pain after SCI, and acrolein scavenger such as 
hydralazine, could be an effective therapeutic strategy to attenuate neuropathic pain for 





1.10 General Characteristic of TRPA1 Channel and Its Activation by Acrolein 
 
TRPA1 channel is a non-selective cation calcium ion channels and consists of six 
trnasmembrane segments (Doerner et al., 2007; Andre et al., 2009; Patapoutian et al., 
2009). The N-terminal and C-terminal of TRPA1 channel are located in the intracellular 
side of membrane. Especially, the long N-terminal contains up to 18 ankyrin repeated 
domains which are involved in the activation of TRPA1 channel. On this ankyrin 
repeated domain, there is EF-hand domain where calcium ions can bind to and activate 
TRPA1 channel. So, calcium ions play a critical role in TRPA1 functioning (Clapham et 
al., 2001; Bandell et al., 2007). In addition, N-terminal cystein residues are responsible 
for electrophile-mediated TRPA1 channel activation.  
 
The gene expression level of TRPA1 was increased in the spinal dorsal horn and 
DRG after SCI (Due et al., 2014). TRPA1 channels have a wide pore which is stimulus 
dependent so that it can regulate the calcium ions permeability (Bandell et al., 2007). In 
this sense, SCI-induced neuropathic pain can increase not only the expression level of 
TRPA1 channels, but the pore size, which lead to influx of much larger calcium ions 
compared to normal physiological condition. Furthermore, TRPA1 channels are 
expressed in C and Aδ primary afferent fiber and many of TRPA1-expression neurons 
are peptidergic neurons which contribute to release of neurotransmitters to postsynaptic 
neurons (Bautista et al., 2006). So, TRPA1 channel on the central ending of primary 
afferent neuron in the spinal dorsal horn might play an important role in the maintenance 
and transmission of pain signaling.  
 
Based on previous studies, TRPA1 channel acts as a sensor for endogenous 
byproducts of oxidative stress-mediated substances (Andersson et al., 2008). These 
byproducts such as acrolein, 4-HNE and H2O2 can directly activate TRPA1 channel 
because of the electrophilic properties of compounds. These electrophilic compounds 
react with nucleophilic thiol group of cystein and ε-amino group of lysine residues in the 
N-terminal of TRPA1 channel via covalent modification. In addition, the reaction 
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between acrolein and thiol group of cystein is reversible so acrolein can break from 
cystein-acrolein adduct and bind to other proteins and/or DNA. Under normal 
physiological pH and temperature, covalent modification on the channel lasts for hours 
which contribute to conformational change of TRPA1 channel. Therefore, membrane 
permeability is the one of the critical fundamental requirements for TRPA1 channel’s 
agonist (Bautista et al.; Bautista et al., 2006; Andersson et al., 2008; Bessac et al., 2008). 
Another possible activation of TRPA1 channel by byproducts of oxidative stress is the 
formation of disulfide bond via oxidation by hydrogen peroxide and again, this 
modification of N-terminal cystein in TRPA1 results in wide the pore size of the channel 
(Bautista et al., 2006; Nilius et al., 2007; Patapoutian et al., 2009).  
 
Other non-electrophilic TRPA1 agonists such as menthol, camphor and icilin do 
not bind to cystein or lysine residue covalently because of their chemical structure 
(Bandell et al., 2004; Bandell et al., 2007). These agonists can stimulate TRPA1 channel 
through a temporal and reversible Fischer lock and key principle. In general, anesthetic 
agents such as lidocaine can promote the activation and sensitization of TRPA1 channel 
(Matta et al., 2008; Piao et al., 2009). Normally these anesthetic agents depress the CNS, 
but also activate peripheral nociceptive sensory neurons by activating TRPA1 channel. 
Furthermore, these effects could integrate with tissue damage during the surgical 
operation, which could result in an increase in post-operative pain and inflammation.  
 
TRPA1 channel also can be activated indirectly through G-protein coupled receptor 
(GPCR)-mediated pathway (Bautista et al., 2006). For example, TRPA1 can be activated 
by pro-inflammatory factor bradykinin (BK)-induced signaling pathway. When BK binds 
to its receptor (bradykinin 2 receptor), intracellular calcium level is increased through a 
phospholipase C (PLC)-mediated down-stream signaling. These calcium ions could bind 
to EF-hand domain of N-terminal of TRPA1 and lead to activation of TRPA1 channel. In 
addition, TRPA1 can be also activated via transient receptor potential vanilloid1 
(TRPV1). TRPA1 channel is most likely expressed with TRPV1 channel. TRPV1 can be 




such as PKC. In addition, heat thermal stimulus can activate the TRPV1 channel. TRPV1 
channel activation lead to an increase in influx of calcium ions into the cytoplasm, and 
these calcium ions could bind to TRPA1 and results in activation of TRPA1 channel. 
Therefore, TRPA1 gates in response to both calcium ions release from intracellular 
calcium ion stores and influx calcium ions after gating TRPV1 channel(Bautista et al.; 
Hinman et al., 2006; Andersson et al., 2008; Bessac and Jordt, 2008).  
 
1.11 Summary and Conclusion 
 
There is strong evidence that acrolein acts as key factor in secondary cascade 
events after primary traumatic SCI. With its reactive, volatile, long half-life and ability to 
generate protein adducts nature, acrolein has been associated with many different types of 
neurological diseases.  
 
In addition, as a strong pro-nociceptive agonist, acrolein can promote sensory 
neurons’ excitability, and reduction current threshold of sensory neuron after SCI. 
Although, more studies are needed to understand the mechanisms about elevation of 
sensitivity on nociceptive sensory neuron via TRPA1 channel or/and acrolein alone, 
many of studied have demonstrated that acrolein could be a valuable therapeutic target to 
improve the SCI-induced neuropathic pain and neurological deficits.  
 
Many of recent studies have demonstrated that acrolein scavenger hydralazine can 
attenuate acrolein-mediated cellular death and toxicity. In addition, hydralazine can 
decrease the acrolein-protein adduct level and offer the neuroprotective effects in in vivo 
SCI animal model. Because half-life of hydralazine is only a few hours (2hours), it might 
be possible that frequent application of hydralazine would provide additional 
neuroprotective effects. Taken all together, acrolein-scavenging strategies might be a 
novel and potential way to improve quality of patients’ life, who are suffering from SCI 
and acrolein-mediated neurological diseases.  
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CHAPTER 2.  NEUROPROTECTIVE ROLE OF ACROLEIN SCAVENGER IN 
SPINAL CORD INJURY RAT MODEL 
2.1 Introduction 
 
Secondary cascade biochemical events after primary traumatic SCI can result in 
spreading the additional damages throughout the spinal cord and amplify the effects of 
traumatic SCI.  
 
Post-traumatic oxidative stress, as a key factor of secondary cascade, plays a 
critical role in the pathogenesis and in mediating functional loss of SCI (Braughler and 
Hall, 1989b). However, treatment with free radical scavengers have been failed to 
produce effective results on clinical trials. We have been demonstrated that acrolein, 
byproduct of LPO and α,β-unsaturated aldehyde, plays an important role in neuronal cell 
death and secondary cascade events after traumatic injury (Shi and Luo, 2006; Hamann et 
al., 2008b; Hamann and Shi, 2009; Shi et al., 2011). Basically, acrolein is very reactive 
and volatile molecule, which concentration is increased in the spinal cord after SCI. In 
addition, with its significantly long half-life, it can stay within biological system 
compared to other types of ROS (Esterbauer et al., 1991a; Ghilarducci and Tjeerdema, 
1995; Picklo and Montine, 2001; Shi et al., 2002a; Luo and Shi, 2004; Liu-Snyder et al., 
2006b; Shi and Luo, 2006). Furthermore, acrolein can bind to proteins, DNA, and lipid 
directly and induce the formation of acrolein-protein adducts (Kehrer and Biswal, 2000b; 
Stevens and Maier, 2008). In addition, with acrolein’s neurotoxicity nature, many studies 
have been also shown that acrolein has been implicated in many of neurodegenerative 
diseases such as degrading myelin (Luo et al., 2005a; Liu-Snyder et al., 2006b).  
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Therefore, acrolein can induce a vicious cycle of oxidative stress and amplifies its 
effects, and also it is responsible for spreading of additional damage throughout the spinal 
cord tissue after traumatic SCI. 
 
Because of important pathological role of acrolein, the detection and measurement 
techniques of acrolein are very important to investigate the acrolein-mediated 
neurodegenerative diseases. Recent study has shown that stable acrolein specific 
metabolite 3-HPMA was generated when acrolein reacted with endogenous antioxidant 
GSH, which could be measured in urine (Carmella et al., 2007; Schettgen et al., 2008). 
Because of its non-invasive method, measuring 3-HPMA has been using to estimate the 
level of acrolein such as acrolein intake via smoke and food (Schettgen et al., 2008). 
 
Based on current understanding of acrolein, we hypothesize that attenuation of 
acrolein might reduce neurological damage and improve the functional recovery after 
SCI. To investigate this hypothesis, and to demonstrate the role of acrolein in SCI, we 
have investigated that the acrolein scavenger, hydralazine, could mitigate acrolein-
mediated cell death (Liu-Snyder et al., 2006b), as well as in isolated spinal cord (Hamann 
et al., 2008a).  In addition, hydralazine could prevent acrolein-mediated toxicity in 
hepatocytes via in vitro test and delayed onset of multiple sclerosis (MS)-induced motor 
neuron dysfunction in mice (Leung et al., 2011b). Although there are many of in vitro 
studies that have investigated the effect of acrolein-scavenger hydralazine via in vitro test, 
anyone hasn’t evaluated the effect of acrolein scavenger therapy using in vivo SCI animal 
model. Without this information, the effect and therapeutic value of acrolein for treatment 
for SCI patients remain uncertain.  
 
In this sense, the primary goal of this chapter is to ascertain the pathological role of 
acrolein in the CNS and the effect of acrolein scavenger hydralazine in live SCI animal 
model. Through this study, we also investigate whether the FDA-approved hypertensive 
medication hydralazine can attenuate acrolein-mediated tissue damage and promote 
functional recovery.  
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Body weight between 210-230 grams male Sprague-Dawley rats were used for this 
study. Rats were housed and handled in compliance with the Purdue University Animal 
Care and Use Committee guidelines. For the acclimation, the animals were kept at least 
one week before surgery. 
 
Contused- spinal cord injury rat model 
  
Animals were anesthetized with a ketamine (80 mg/kg) and xylazine (10 mg/kg) 
mixture by an intraperitoneal (IP) injection. A dorsal surface of spinal cord at the T-10 
level was exposed by removing spinous process and vertebrae lamina. We made two 
different severities contusion models by using New York University (NYU) impactor. 
Basically, NYU impactor has a 10-gram of weight rod with 1.5 mm. By dropping this 
weight rod from different height, we can generate different severity of contused-SCI 
model. In this study, we dropped the weight rod form 25mm onto the intact T-10 level of 
spinal cord to generate moderate contused-SCI model. For severe contused-SCI model, 
we dropped it onto the spinal cord from 37.5mm. The sham control was operated using 
only a laminectomy at the T-10 level. For the post-surgical care, the animals were placed 
on a heating pad and performed manual bladder expression daily two times until the 
reflexive control bladder function was observed, and to prevent dehydration, 3.0 cc of 




The hydralazine hydrochloride (Sigma, St. Louis, MO, USA) was dissolved in 
sterilized phosphate buffered saline (PBS). 5mg/kg of hydralazine solution was injected 
via I.P. injection daily for two weeks, right after SCI within 5 minutes. For 
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immunoblotting study, hydralazine solution was administrated by I.P. injection right after 
surgery and 24 hours after SCI. Then, animals were euthanized two hours injection to 
collect spinal cord injury sites. The dosage of hydralazine solution 5mg/kg was decided 
based on previous study (Zheng et al., 2013). They have demonstrated that 5mg/kg of 
hydralazine showed not only the effectiveness of acrolein reduction, but the minimal 
influence of blood pressure to the animals. 
 
Quantification of hydralazine in the central nervous system 
 
Paper spray mass spectrometry was used to quantify the concentration of 
hydralazine in the spinal cord, and brain. To quantify the concentration of hydralazine in 
the tissues, first, we collected tissues from the untreated animals, which were spiked 
artificially with different concentration of hydralazine from 15.63 ng/ml to 2000 ng/ml. 
For the internal control, the fixed concentration of nicotine was used. Based on these data, 
we constructed a calibration curve. In the experiment group, saline was injected as a 
control and 5mg/kg of hydralazine was injected then, animals were sacrificed two hours 
after injection. Collected samples were punched and transferred onto the paper for paper 
spray mass spectrometry analysis and measurement of hydralazine level. The final 




For the urine collection from the animals, we used the standard metabolic cages. 
Drinking water and urine collection were separated to avoid urine dilution by water 
source. During the urine collection, food was also provided. To collected enough urine 
for the study, 0.5 cc of saline was injected via subcutaneously at each collection time. 








We measured the creatinine level with a creatinine (urinary) assay kit (Cayman 
Chemical Company, Item No. 500701). Original urine sample were diluted for 12 and 24 
times before the creatinine assay. According to the assay manual, all required agents were 
prepared. Then, all diluted urine samples and creatinine standards were incubated on the 
shaker with the alkaline picrate solution for 15 mins. Using standard spectrophotometry, 
the samples were read at 492 nm then, 5 ul of acid solution were added to all samples 
after initial reading. The plate also was placed on the shaker for 15 mins. The differences 
wave absorbance between the initial reading and final reading were used for analysis.  
 
3-hydroxypropyl mercapturic acid (3-HPMA) Analysis in Urine 
 
3-HPMA was analyzed in urine according to Eckert et al (Eckert et al., 2010). For 
using LC/MS/MS solid phase extraction with isolute ENV+ cartridge (Biotage, Charlotte, 
NC) was used to prepare each sample. Each cartridge was washed with 1ml of methanol, 
1 ml of water, and 1 ml of 0.1% formic acid in water. A volume of 500 µl deuterated 3-
HPMA (d3-3-HPMA) were spiled with 200ng, which was then mixed with 500 µl of 
50mM ammonium formate and 10 µL of undiluted formic acid. This mixture was loaded 
into the ENV+ cartridges. After the samples loading, using 1 ml of 0.1% formic acid, and 
1 ml of 10% methanol/90% 0.1% formic acid in water, washed each cartridge twice. Next, 
under the nitrogen gas, the cartridges were dried for 30mins, then, using three volumes of 
600 µl methanol with 2% formic acid, all cartridges were eluted. The eluates were dried 
in the evaporate device. Right before loading the samples into the LC/MS/MS, each 
sample was reconstituted in 100 µl of 0.1% formic acid. The LC/MS/MS using and data 







Locomotor behavioral test 
 
The functional motor neuron recovery was investigated by using the Basso, Beattie 
and Bresnahan (BBB) Locomotor Rating Scale (Basso et al., 1996). The BBB locomotor 
scores are based on the ability of SCI rat’s hind limb movement. For example, BBB score 
0 means that there is no observable movement of rat’s hind limb, and 21, which is 
maximum score, means that movement of normal rat. For the test, the rats were placed in 
an open field for 5 mins for the acclimation, then observe the movement of left and right 
side of hind limb separately. BBB score were assessed at day one and weekly for four 
weeks after SCI.  
 
Neuropathic pain assessment 
 
50% up-down method was used for mechanical allodynia test (Chaplan et al., 1994). 
Briefly, SCI animals were placed in a plastic acrylic box on the top of a metal mesh. For 
the acclimation, left them alone at least 10 mins then test was performed by using von 
Frey filaments. As mechanical stimuli, we used calibrated von Frey filaments which 
range from 0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0 and 15.0 grams (stoelting, Wood Dale, IL, 
USA). Initially, 4 grams of von Frey filament was applied perpendicularly with a 
sufficient bending force to the plantar surface of the hind-limb for 3-5 sec then removed. 
A brisk movement and/or licking and/or biting were considered as a positive reaction, 
then a lower von Frey filament was applied to the same spot. If there was no positive 
response, the next greater filament was presented. Different stimulus of filaments were 
applied at least 1 min interval.  
 
Isolation of spinal cord 
 
Initially, animals were anesthetized deeply with a mixture of ketamone (80mg/kg) 
and xylazine (10mg/kg) via I.P. injection. Then, they were perfused with oxygenated cold 
Kreb’s solution (124mM NaCl, 2mM KCl, 1.24 mM KH2PO4, 26 mM NaHCO3, and 10 
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mM ascorbic acid, 1.3 mM MgSO4, 1.2 mM CaCl2, and 10 mM glucose). To isolate 
spinal cord, first, the whole vertebral column of rat was removed and we performed a  
dorsal laminectomy along the vertebral column. Collected spinal cord was cut into 1 cm 
long for immnoblotting for acrolein level detection and for histological analysis.  
 
Artificial acrolein standard preparation 
 
For the immunoblotting, the artificial acroelin standard was prepared. Initially, rat 
albumin (0.5 ml of 2mg/ml, CalBioChem) solution and acrolein (0.5ml of 100 mM, 
Sigma) solution were mixed together, which was incubated for 4 hours at 37 degree C. 
Using 0.1% BSA, we performed serial dilution up to 10000 fold with the acrolein 
concentration ranging from 5uM (or 100ng/ml) to 25nM (or 0.5ng/ml). The standard 
smaples were loaded and measured, then we measured the band intensities by using 
Image J (NIH). Based on these bands density, we constructed the calibration acrolein 
standard curve. So, acrolein level in the interest samples can be measured from this fitted 




Spinal cord segments which include damage site were incubated with a 1% Triton 
solution with the corresponding amount of Protease Inhibitor Cocktails (Sigma Aldrich), 
then homogenized with sonicator for 10 sec. The homogenized tissue suspension was 
incubated in the ice for 1 hour then, centrifuged at 4 °C at 13500g for 30 mins. Using 
BCA protein assay kit, we measured the total protein concentration from each sample for 
the equal sample loading. 200μg of samples were transfer to the nitrocellulose membrane 
by using a Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA, USA). Next 
this transferred membrane was blocked in 0.2% casein and 0.1% Tween 20 in PBS 
blocking buffer for 1 hour and incubated with monoclonal mouse anti-acrolein antibody 
(ABCAM) for at least 18 hours at 4 °C. An anti-acrolein antibody was diluted at a ratio 
of 1:1000 in blocking buffer with 2% goat serum and 0.025% sodium azide. The 
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membrane was washed 4 times in blocking buffer for 4 mins then, the membrane was 
transferred to 1:10000 alkaline phosphatase conjugated goat anti-mouse IgG solution for 
another hour (VECTASTAIN ABC-AmP Kit). For the final washes, we used blocking 
buffer and 0.1% Tween 20 in Tris-buffered saline then, the membrane was exposed to 
substrate of the ABC-AMP kit and visualized by chemiluminescence. The band density 
was assessed by Image J (NIH) and using an arbitrary unit for the expression.  
 
Histology of rat spinal cord injury 
 
For the tissue collection, initially we perfused animals with oxygenated cold Kreb’s 
solution then followed by 10% formalin. The removed spinal cord was into 10% formalin 
for the post fixation for 24 hours then, embedded in paraffin. Tissues were cut with 10 
µm thickness through horizontal section and stained with luxol fast blue and cresyl violet. 
The cyste area was quantified by measuring the percent area of the cyst relative to the rest 
tissue area on the section, then we took an average two adjacent sections at the spinal 
cord mid-line. The area was compared between hydralazine treatment and non-treatment 
group with a Student’s T-test.  
 
Acrolein microinjection into spinal cord and histological analysis 
 
After deep anesthesia, we performed laminectomy at T-10 level to expose intact 
spinal cord. The micro-pipettes were pulled and beveled for the insertion into the spinal 
cord. Micro-pipette was loaded with saline as a control and acrolein in saline as an 
experimental group. The solution was injected using a three-way valve and a syringe 
under the negative pressure. For the injection, we used the PMI-100 oressure micro-
injector (Dagan Corp., Minneapolis, MN). 1.6 µl of saline was injected into rat’s left side 
of spinal cord as a control and 1.6 µmol of acrolein in saline was injected into rat’s right 
side of spinal cord. Specifically, each solution was injected 0.6 mm lateral to the spinal 




surgical care, rat was placed on the heating pad and anti-biotic ointment was applied to 
the incision site.  
  
For the histological analysis, we performed hematoxylin and eosin staining on the 
spinal cord 2 weeks after surgery. Paraffin embedded spinal cord samples were cut into 
longitudinally with 15 µm thickness by using AO829 microtome (American Optical, 
Buffalo, NY). After staining with hematoxylin and eosin, images were acquired by 
Olympus microscope at 4X and followed by Image J for the analysis. 
 
Statistical analysis  
 
For the data comparison between two groups, we performed Student’s t-test 
method and for the more than two variables, we used ANOVA and Tukey test. If the p 
value is smaller than 0.05, we considered the data is statistically different. All the 




The increase of acrolein level after SCI 
 
We have measured the acrolein level after SCI by using immunoblotting. The data 
have shown that acrolein level was significantly increased in moderate and severe SCI 
compared to the acrolein level in sham control group at both 1 day and 14 days after SCI 
(Figure 7). Specifically, the levels of acrolein in sham, moderate, and severe SCI were 
9.1±5.3, 31.1± 4.0, and 42.7±3.1 respectively. There were significantly difference in 
acrolein level between sham and moderate SCI also between sham and sever SCI group 
at 1 day after SCI. Similar to this, acrolein levels in 14 days after SCI were 8.5±3.6, 
15.3±4.0, and 34.7±3.6 respectively. There were statistically differences in acrolein level 







Figure 7. Elevation of Acrolein Level in Spinal Cord Based on the SCI Severity. 
 
Acrolein-lysine adduct level based on the SCI severity was detected by using 
immunoblotting at different time points (1 day and 14 days after SCI). The bar graph 
showed that acrolein levels were significantly increased in moderate and severe SCI 
compared to sham control group at both 1 day and 14 days after SCI. In addition, 
acrolein level was correlated with SCI severity which indicated that sever SCI 
showed the highest level of acrolein. This data also indicated that acrolein level was 
persisted at least 14 days following SCI. For the comparison, acrolein arbitrary unit in 
moderate and severe were 31.09± 4.0 and 42.69±3.13, which were significantly 
higher than that of shame (9.13±5.29, p <0.005) at day 1. Also, acrolein level in 
severe SCI at day 14 was 34.73±3.64, which was also significantly higher than that of 
sham (8.53±3.57, p<0.005). There was no difference between moderate and sham at 
14 days after SCI. For the data analysis, one way ANOVA and post hoc tests were 









Elevation of urine 3-HPMA levels from SCI 
 
To determine the endogenously generated acrolein level after SCI, we 
measured the 3-HPMA level using rat urine samples from different SCI severity 
groups. Similar to acrolein level in different SCI severity group, 3-HPMA levels also 
were correlated with SCI severity (Figure 8). Specifically, we collected rat urine 24 
hours after SCI and 3-HPMA levels were 1.99±0.21, 3.51±0.24, and 5.51±1.13 μg/mg 
in sham, moderate and severe SCI group. These data showed that 3-HPMA level of 
moderate SCI was higher than that of sham (p<0.05) and 3-HPMA level of severe 
group was also higher than that of moderate SCI (p<0.05). Taken together, elevation 
of 3-HMPA level also correlated with SCI severity.  
 
The level of hydralazine in CNS following IP injection  
 
Before test the benefit of acrolein scavenger hydralazine, we investigated 
whether it could reach therapeutic level in the CNS after I.P injection. According to 
the previous study, half-life of hydralazine was about 2 hours, so we euthanized the 
animals 2 hours after hydralazine systemic application (5mg/kg) and then, the brain 
and spinal cord was removed. Hydralazine level was measured by using paper spray 
mass spectrometer. The results data has shown in figure 9. First of all, there were 
significant levels of hydralazine in the CNS within two hours after systemic 
application. Specifically, the detected level of hydralazine in the brain and spinal cord 
were 2.92 ± 0.88 and 4.42 ± 1.11 µg/g (29.47 ± 4.65 and 19.87 ± 4.42 µM), while, 
there was no detected hydralazine concentration in control group. Based on previous 
in vitro test, minimal level of hydralazine to attenuate acrolein-mediated cellular 
death was no higher than 20 µM. So, this data indicated that hydralazine could reach 
the CNS using systemic application and its concentration was enough to provide the 












Figure 8. Correlation of 3-HPMA Level with SCI Severity 
 
The urine samples from sham control, moderate SCI, and severe SCI were collected 
24 hours after SCI for the 3-HPMA study. Similar to acrolein level, 3-HPMA level 
also correlated with SCI severity. The 3-HPMA levels were 1.99±0.21, 3.51±0.24, 
and 5.51±1.13 μg/mg respectively. Specifically, 3-HPMA level in severe SCI showed 
the highest level compared to any other groups. N=4-6 for each group. For the 




















Figure 9. Detection Hydralazine Level in the CNS after Systemic Application. 
 
A) 5mg/kg of hydralazine solution was injected through systemically and same 
amount of saline was used for the control group. Two hours after injection, the brain 
and spinal cord tissues were removed to determine level of hydralazine. B) 
hydralazine level was determined using paper spray mass spectrometer. The data 
showed that level of hydralazine in the CNS were 29.47 ± 4.65 and 19.87 ± 4.42 µM 
respectively. No hydralazine level was detected in saline control group. This data 
demonstrate that systemic application of hydralazine could reach the CNS within two 












Acrolein scavenger hydralazine can effectively decrease acrolein level in 
SCI animal model 
 
We have confirmed that hydralazine could reach the CNS with the therapeutic 
level. Next, to test if the acrolein scavenger hydralazine could reduce the acrolein 
level after SCI, we injected 5mg/kg of hydralazine right after SCI surgery within 5 
mins and gave the second injection two hours before the animals were euthanized. As 
shown in figure 10, acrolein scavenger hydralazine could significantly reduce the 
acrolein-lysine adduct level after SCI. The data indicated that in both moderate SCI 
and severe SCI, the levels of acrolein were reduced by more than 50% after 
hydralazine application. This data supported that acrolein scavenger hydralazine 
could reduce the acrolein level after SCI effectively. 
 
Acrolein scavenger hydralazine can decrease the urine 3-HPMA level 
after SCI 
 
Again, urine 3-HPMA level was measured to confirm the effect of hydralazine 
as an acrolein scavenger. For this study, 5mg/kg of hydralazine was injected for seven 
days daily and urine also collected every 24 hours for seven days. Initially, 3-HPMA 
level was significantly increased in SCI group in the first three days after operation 
(Figure 11). Specifically, 3-HPMA levels were 3.51±0.24, 2.96 ±0.20, and 2.49±0.12 
μg/mg, respectively. However, 4 days post injury, the level of 3-HPMA were as low 
as that of control. Hydralazine treatment group showed that the level of 3-HPMA at 
one day after SCI was significantly lower than that of SCI only group. However, there 
was no difference between hydralazine treatment group and SCI only group in the 

















Figure 10. Hydralazine can Reduce the Acrolein-lysnie Adduct Level after SCI 
 
Using immunoblotting, we measured the acrolein-lysine adduct level after 5mg/kg of 
hydralazine injection. Hydralazine was injected two times before collecting spinal 
cord (right after SCI within 5 mins and 2 hours before euthanizing). The data results 
showed that the level of acrolein-lysine adduct was significantly decreased from 
30.35+5.34 to 8.94+7.44 in moderate SCI rats and from 43.45+4.34 to 22.45+3.56 in 
severe SCI rats. For the band densities’ analysis, Image J was used. N=6 in all groups 
and p<0.05 in both moderate and severe groups between hydralazine treatment and 

















Figure 11. Urine 3-HPMA Level Reduction by Hydralazine 
 
To determine effect of hydralazine, urine 3-HPMA was detected from SCI rat for 
seven days. Urine was collected every 24 hours for seven days and 5mg/kg of 
hydralazine was injected daily. 3-HPMA level was significantly decreased 1 day after 
hydralazine injection. N=4 in each group ( : P < 0.05 when compared to control; #: P 















Hydralazine significantly reduces tissue damage after SCI 
 
We measured the cyst area to determine whether the hydralazine could reduce 
the neurological damage after SCI. To quantify the area of cyst, we took an average 
two adjacent longitudinal sections at the spinal cord mid-line and stained by luxol fast 
blue method (Figure 12). There was no cyst area in control group, however, cyst 
covered about 37.99% of the tissue on SCI group. When we treated with hydralazine, 
the cyst area was significantly decreased (from 37.99% to 11.39%). This data 
demonstrated that acrolein scavenger hydralazine could reduce area of cyst formation 
after SCI.  
 
Hydralazine improves locomotor function recovery in rat SCI 
 
The locomotor function recovery was assessed by using BBB scale one day 
after SCI and once a week for four weeks (Figure 13). As a base line, BBB score in 
whole groups showed 21 points. However, one day after SCI, all animals scored 0 
which indicated no movement. For the treatment group, 5mg/kg of hydralazine was 
injected every day for 14 days. The BBB score in hydralazine injection group was 
significantly increased compared to SCI only group starting at seven days after 
hydralazine injection. Significant differences BBB score were maintained until 4 
weeks. Specifically, the BBB score in SCI with hydralazine treatment group was 
16.12 ± 1.03, and BBB score in SIC only group showed 12.44 ± 1.17 which was 
significantly lower than that of hydralazine treatment group (p<0.05). The BBB score 
in Sham injury group was 18.45±1.05 one day after SCI, but one week after SCI, we 
observed normal locomotor function (BBB score 21). During the test periods, there 
















Figure 12. The Effect of Hydralazine on Cyst Area Reduction after SCI 
 
Cyst area was quantified 4 weeks after SCI using saline injected uninjured spinal cord, 
SCI only spinal cord, and SCI with hydralazine treatment group. A-C) Luxol fast blue 
staining showed the size of cyst area in the spinal cord. (A) uninjured saline injection 
site, (B) SCI only, and (C) SCI with hydralazine injection spinal cord. The cyste area 
in hydralazine treatment group was significantly smaller than SCI only group 


















Figure 13. Systemic Application of Hydralazine Increased Motor Function 
Recovery after SCI 
 
SCI animals’ locomotor function was assessed by BBB score. Before SCI surgery, all 
group showed normal gaits (21 points). One day after SCI, BBB score in all groups 
were 0 except sham injury group. Acrolein scavenger hydralazine (5mg/kg) was 
injected for 14 days daily. One week after SCI, the BBB score in hydralazine 
treatment group was statistically higher than SCI only group and this trend kept 
maintained until 4 weeks. Specifically, the BBB score in hydralazine treatment group 
was 16.12 ± 1.03 and that in SCI only was 12.44 ± 1.17 (p<0.05). There was no 













Hydralazine attenuated acute neuropathic pain behavior following SCI 
 
In addition to the functional benefits of hydralazine on motor function 
recovery, we also tested the effect of acrolein scavenger hydralazine on sensory 
dysfunction in SCI. Specifically, we investigated whether hydralazine could attenuate 
the neuropathic pain behavior through reduction in acrolein level after SCI. For this, 
again, 5mg/kg of hydralazine was injected systemically for two weeks every day. 
Neuropathic pain behavior, allodynia, was assessed by using von Frey filaments. SCI 
animals’ mechanical threshold was measured one day before SCI as a base line, and 
started at 2 weeks after SCI (Figure 14). Normally, mechanical allodynia test could be 
started when the SCI animals could support their body weight via their hindlimb and 
figure 14 showed that two week after SCI, mechanical allodynia was well established. 
Based on 50% up-down method, the maximum threshold is 15.0g and minimum 
threshold is 0.25g (Chaplan et al., 1994). The base lines of control, sham, SCI only, 
and SCI with hydralazine treatment were 14.02 ± 0.8 g, 14.65 ± 0.3 g, 14.3 ± 0.7 g 
and 13.92 ±1.0 g, respectively. During the test periods, there were no changes of 
mechanical threshold in control and sham injury groups. However, mechanical 
threshold in SCI only group was significantly lower than that in SCI with hydralazine 
treatment groups at two weeks after SCI. In addition, neuropathic pain behavior was 
significantly decreased in SCI with hydralazine treatment group during test period 
compared to SCI only group. Specifically, mechanical threshold in SCI only was 8.1 
± 1.2 g at two weeks after SCI, which was significantly higher than that in SCI with 
treatment group, which was 3.71 ± 0.28 g. We could check similar mechanical 
allodynia reductions in hydralazine treatment group during the test. Basically, the low 
mechanical threshold means less sensitive to mechanical stimulus. So, this data 
demonstrated that acrolein scavenger hydralazine could attenuate the neuropathic 















Figure 14. Hydralazine Alleviated Mechanical Threshold after SCI 
 
Systemic application of hydralazine alleviated neuropathic pain allodynia after SCI. 
No neuropathic pain behaviors were observed in control and sham. However, 
mechanical threshold in SCI only group was significantly lower than that in sham 
group during the test period. Mechanical threshold in hydralazine treatment was 
significantly higher than that in SCI only. This data showed that acrolein scavenger 
hydralazine can attenuate neuropathic pain after SCI. # p<0.05, ## p<0.01 for 
comparison between sham and SCI. * p<0.05, ** p<0.01 for comparison between 












Acrolein micro-injection into the spinal cord resulted in neurological 
motor function deficits and tissue damage 
 
Next, we investigated whether the acorlein itself could induce the neurological 
deficits such as motor dysfunction and neural tissue damage without traumatic injury. 
For this, we injected a certain amount of acrolein into the animal’s right side of spinal 
cord, and the same amount of saline was injected into the animal’s left side of spinal 
cord directly (Figure 15). For the motor function evaluation, we performed BBB 
locomotor test every 2 days for 14 days on each right and left hind limb. As shown in 
figure 15B, BBB score, the motor function of contralateral side of acrolein injection 
side was significantly lower than saline injection site, which was persistent during the 
test period. This data showed that acrolein could produce motor function deficit.  
 
In addition, acrolein alone can produce the neuronal damage on tissue. The 
eosinophilic lesion area was surrounded by notable glial scar tissue with a number of 
small nucleus cells. However, there was no glial scar formation on saline injection 























Figure 15. Acrolein can Induce Neurological Deficits without Mechanical Injury 
 
A) Acrolein and saline injection site into the spinal cord and the tissue section plan 
for histology in (C). B) Micro-injected acrolein into the spinal cord could induce the 
motor function deficits. Motor function was evaluated via BBB score, which was 
significantly lower in acrolein injection site compared to that of saline injection site. 
This trend lasted for 2 weeks. The values are mean±SEM.  p < 0.01 for comparison 
between right side (acrolein-injected) and left side (saline injected), Student’s t-test. 
N=6 in each group. C) H and E staining was used for histological analysis. There was 
no morphological in saline injection site, while there was massive glial scar formation 
in acrolein injection site. The inset indicated the enlarged acrolein injected area which 









2.4 Discussion  
 
In this current study, we have demonstrated that the acrolein level was 
significantly increased in contusion rat SCI model and elevated acrolein could be 
decreased via acrolein scavenger hydralazine treatment. In addition to removing 
acrolein, systemic application of hydralazine also could lead to a decrease in the 
tissue damage, locomotor dysfunction, and neuropathic pain behaviors. Furthermore, 
acrolein itself could result in neurological damage and motor function deficits without 
any mechanical traumatic injury, which were very similar to the SCI-induced 
neurological disorders such as tissue damage and motor neuron malfunction. These 
data were supported by many of previous studies that acrolein scavenger hydralazine 
could reduce acrolein-mediated cellular death via in vitro study (Shi and Blight, 1996; 
Liu-Snyder et al., 2006b; Hamann et al., 2008b; Hamann et al., 2008a). Therefore, 
current study demonstrated that acrolein plays an important role in the pathogenesis 
of spinal cord mechanical injury.  
 
This study has showed that acrolein level increased in contused spinal cord 
injury rat model. This is the first research that proved the elevation of acrolein in the 
SCI rat, even though there was previous research showing the increased acrolein level 
in compression-injured spinal cord from guinea pig (Luo et al., 2005b). In addition, 
we have demonstrated that acrolein level was significantly increased even two weeks 
after SCI (Figure 7), while Luo et al. showed the elevated acrolein level in only one 
week time period in guinea pig spinal cord. In addition, our data showed that the 
maximal increase of acrolein after rat spinal cord injury was 300%, however, 
increased level of acrolein in guinea pig spinal cord was 60% based on their ELISA 
data . There are some different between two studies because of using different animal 
species and different type of injury model (contusion vs. compression SCI model). 
Also, there were differences in measuring techniques (immunoblotting vs. ELISA). 
However, both of studies showed that the acorlein reached the highest level 24 hours 
after SCI. So, these two studies demonstrated that the level of acrolein after SCI peak 




By using paper spray mass spectrometer (Wang et al., 2011), we have 
demonstrated that systemically injected hydralazine could reach the brain and spinal 
cord within two hours. The data showed that the concentration of hydralazine in the 
CNS was 20 μM in the spinal cord and 30 μM in the brain. Based on the previous 
study, the minimal level of hydralazine to mitigate the acrolein-mediated neuronal 
cell death was no more than 15 μM (Liu-Snyder et al., 2006b), which was within 
hydralazine concentration range in the spinal cord after systemic application. Many of 
studies have shown that acrolein scavenger hydralazine could attenuate neuronal 
damage by using neural cell culture, and ex vivo studies using isolated spinal cord 
(Liu-Snyder et al., 2006b; Hamann et al., 2008b; Hamann et al., 2008a; Hamann and 
Shi, 2009). This study is the first one that demonstrates the benefits of acrolein 
scavenger hydralazine as a neuroprotective agent via in vivo study. The estimated 
hydralazine concentration through ex vivo or in vitro cannot be applied to the in vivo 
study because of its complexity. Therefore, spray mass spectrometer data provided 
the valuable aspects for hydralazine application to the in vivo study.  
 
Our data have demonstrated that systemic application of hydralazine could 
reduce acrolein level in the spinal cord following SCI by 50-70% and level of 3-
HPMA in urine. This data supported that the benefit of hydralazine as a 
neuroprotective agent not only in vitro, but in vivo. Because we have injected 
hydralazine once a day and half-life of hydralazine is only a few hours, more frequent 
application of hydralazine would provide more benefits in attenuate acrolein level 
follow SCI.  
 
We have demonstrated that hydralazine also could reduce the formation of cyst 
after SCI, which is a severe form of tissue damage and known as syringomyelia in 
traumatic spinal cord (Nurick et al., 1970; Mudge et al., 1984; Schurch et al., 1996; 
Rooney et al., 2009). This cyst area (Figure 12) would be the scar tissue such as seen 
in figure 15. Therefore, the reduction of cyst area by application of hydralazine could 




chemical barrier for axon elongation after SCI (Giger et al.; Nguyen et al., 2009; Park 
et al., 2010).  
 
In addition to the reduction of cyst area, our data demonstrated that hydralazine 
application could not only improve locomotor dysfunction (Figure 13), but attenuate 
neuropathic pain mechanical allodynia after SCI (Figure 14). Neuropathic pain is the 
one of major symptoms that at least 80% of SCI patients are suffering from this 
neurological disease (Hulsebosch et al., 2009). Acrolein is also known as pro-
inflammatory factor and stimulates the generation of various inflammatory 
compounds which are responsible for neuropathic and inflammatory pain after SCI 
(Facchinetti et al., 2007; Moretto et al., 2009). Especially, inflammation is the one of 
the main reasons that contribute to onset and maintenance of neuropathic pain after 
SCI (Schnell et al., 1999; Jones et al., 2005; White et al., 2005; Trivedi et al., 2006; 
White et al., 2007; Donnelly and Popovich, 2008; Hulsebosch, 2008). Therefore, it is 
reasonable to estimate that acroelin-mediated inflammation could result in onset of 
neuropathic pain. In this sense, acrolein scavenger hydralazine could attenuate the 
neuropathic pain behavior by reduction of inflammation reaction through acrolein 
removing. Taken together, acrolein scavenger hydralazine could be an effective 
analgesic to reduce neuropathic pain behavior, and also could be an effective 
treatment to improve the motor function recovery for SCI patients.  
 
The results of this study demonstrated that actolein could be a valuable 
therapeutic target for neurological diseases and its scavenger hydralazine has a 
potential value as analgesic to mitigate the neuropathic pain, and agent to improve the 
motor function recovery after SCI. In spite of many of benefits of hydralazine, 
hydralazine has some limitations as an acrolein scavenger for SCI patients. Basically, 
hydralazine is the FDA-approved hypertensive mediation. However, hypotension 
effect by hydralazine could be a life threatening side effect to especially SCI patients 
because of neurogenic shock. In this sense, the other acrolein scavengers, which do 
not have a hypotension effect, are needed to be studied for SCI patients. FDA-





is not a vasodilator and its half-life is much longer than that of hydralazine (Cole and 
Weiner, 1960; Wood et al., 2006a). Therefore, it could provide more neuroprotective 
effect to SCI patients.  
 
Through this study, we have demonstrated that the pathological role of acrolein 
in SCI and the benefits of acrolein scavenger hydralazine on sensory and motor 
function abnormalities. Since crlinical trials with ROS scavengers have failed to 
produce neuroprotection effect to SCI patients because of its various side effects 
(Constantini and Young, 1994; Chen et al., 1996), acrolein scavenging could be a 
novel and effective way to remove the oxidative stress and promote neuronal 
recovery (Anderson et al., 1994; Behrmann et al., 1994; Bartholdi and Schwab, 1995; 
George et al., 1995; Pereira et al., 2009). In addition, acrolein scavenging therapy also 
would provide neuroprotective effect to not only SCI patients, but other neuronal 
disorder patients, especially, acrolein-related neurodegenerative diseases such as 
multiple sclerosis (Smith et al., 1999; Leung et al., 2011b; Shi et al., 2011), 
Alzheimer’s disease (Lovell et al., 2001a; Montine et al., 2002). Therefore, acrolein 




CHAPTER 3. ACROLEIN INVOLVEMENT IN SENSORY AND BEHAVIORAL 
HYPERSENSITIVITY FOLLOWING SPINAL CORD INJURY 
3.1 Introduction 
 
Chronic neuropathic pain after traumatic SCI significantly impairs the quality of 
SCI patients’. As a matter of fact, beyond paralysis, chronic neuropathic pain further 
drastically impairs the quality of life for SCI victims. Despite years of research, this type 
of clinical pain remains refractory to treatment. As a result, chronic neuropathic pain 
could be prolonged for several decades after SCI and lead to depression and suicide 
(Segatore, 1994; Cairns et al., 1996).  
 
Based on previous study, at least 80% of SCI patients are suffering from 
neuropathic pain, which is felt like burning, stabbing and electric shock like (Hulsebosch, 
2008; Hulsebosch et al., 2009), and felt through the whole body, but patients describe the 
location of pain is below or near the injury site level (Siddall et al., 2003). In the rodent 
SCI-induced neuropathic pain model, the possible explanations for the pain at the below 
injury level are, first, after SCI there could be anatomical changes. For example, the 
central terminal of non-nociceptive primary afferents Aβ fibers could make new 
synaptical connection with nociceptive neurons in laminae I and II. These anatomical 
changes after SCI can cause the persistent hypersensitivity. Second, the changing in 
excitatory interneuron after SCI. Under the neuropathic pain condition, there could be an 
increased in release of excitatory neurotransmitter such as glutamate, which can bind to 
its receptor NMDA. As a result, increased in calcium ion influx via NMDA receptor can 




maintain the activation of pain transmission in dorsal horn and lead to hypersensitivity to 
the stimuli. Third, there could be an interruption in the inhibitory interneurons such as 
GABAergic and/or glycinergic inhibitory interneurons after neuronal damage 
(disinhibition). Therefore, loss of inhibitory effect can result in perceiving normally in-
noxious stimuli as painful stimuli, which can contribute to the generation of neuropathic 
pain after SCI. Lastly, glial cells can also lead to neuropathic pain after SCI. After SCI, 
glial cells release various cytokines, which can bind to excitatory interneuron, and lead to 
signal transduction down-stream to stimulate the central sensitization (Bruce et al., 2002; 
Hains et al., 2003; Lu et al., 2008; You et al., 2008; Bedi et al., 2010; Wang et al., 2012).  
 
Many of studies have demonstrated that the possible mechanisms for generation of 
neuropathic pain after neurological damage, which including ionic channel imbalances, 
release of pro-inflammatory factors, anatomical changes, and malfunction of neuro-glial 
cells. However, the possible role of byproduct of LPO, acrolein, and acrolein-protein 
adducts as important factors have been underestimated.  
 
Acrolein, α,β-unsaturated aldehyde, is a byproduct of LPO (Esterbauer et al., 
1991b; Hamann and Shi, 2009; Shi et al., 2011), and transient receptor potential ankyrin 
1 (TRPA1) channel specific agonist, which are most likely expressed on peptidergic 
nociceptive sensory neuron (Bautista et al., 2006). Acrolein has been implicated in many 
of neurodegenerative disease with its reactive and long half-life properties, which could 
induce the vicious cycle of oxidative stress and enhance its effect (Shi et al., 2011; Wang 
et al., 2011). As a specific agonist for TRPA1 channel and pro-inflammatory agent, 
increase level of acrolein could lead to the generation of neuropathic and inflammatory 
pain after neuronal damage (Story et al., 2003; Bautista et al., 2006; del Camino et al., 
2010). One of the previous studies showed that persistent elevated acrolein level at least 
two weeks after SCI and it could result in onset of neuropathic pain allodynia after SCI 





The FDA-approved hypertensive medication hydralazine has shown that its ability 
to react with acrolein and acrolein-protein adduct and neutralized them (Burcham and 
Pyke, 2006). Based on previous studies, acrolein scavenger hydralazine can mitigate 
acrolein-medicated cellular, cytotoxicity (Hamann et al., 2008a; Hamann and Shi, 2009) 
and damaged spinal cord by compression injury (Luo et al., 2005b). Although we do not 
know yet the degree to which acrolein involve in SCI-induced neuropathic pain behavior, 
acrolein scavenger hydralazine may provide effective therapeutic strategy for people who 
are suffering from neuropathic pain after SCI through scavenging acrolein and acrolein-
protein adducts. The goal of this chapter is to investigate the hypothesis that acrolein can 
increase excitability of SCI-derived DRG sensory neurons, and hydralazine can attenuate 
the neuropathic pain behavior via SCI-induced acrolein and acrolein-protein adducts 
scavenging.  
 




See Chapter 2 
 
Contusion spinal cord injury rat model 
 




See Chapter 2 
 
Neuropathic pain mechanical allodynia test 
 






See Chapter 2 
 
Isolation of spinal cord 
 




See Chapter 2 
 
Neuropathic pain cold allodynia test  
 
Cold allodynia was measured using 100% acetone-induced cooling test. Animals 
were placed on the metal mesh in the transparent plastic box for at least 10 mins for 
acclimation. Then, 0.05 ml of acetone was applied to the animals’ plantar paw skin from 
a distance of 2 mm from paw surface. The acetone was applied 5 times to each paw skin 
and took an average a withdrawal frequency. To prevent from sensitivity to cold stimulus, 
we waited 5 min in between tests. The brisk withdrawal movement and/or licking and/or 
biting behaviors are considered to be a positive response.  
 
For the neuropathic pain behavioral tests, to minimize the stress to the animals, the 
least stressful factor was applied first. Therefore, in this study, the order of the pain 
behavioral test was mechanical allodynia von Frey filament assay and then cold allodynia 
acetone-induced cold test. The tests order was maintained throughout the experimental 
period for all animals. In addition, we performed two different behavioral tests at interval 






RNA isolation and cDNA synthesis 
 
For the real time PCR (RT-PCR), we collected L1-L6 DRG cells from sham and 
SCI animals 1 week after SCI. Total RNA was isolated from samples using 1 ml of Trizol 
reagent (Sigma-Aldrich, St. Louis, MO). Isolated RNA was extracted by chloroform and 
precipitated by isopropanol. RNA concentration was determined using NanoDrop 2000c 
(Thermo Scientific, DE, USA). Then, the extracted RNA was dissolved in 50ul of 
RNase-free distilled water and stored at -80  deep freezer until in use. cDNA was 
synthesized by iScript™ cDNA Synthesis kit manual guide (BIO-RAD,170-8890,USA) 




Primers were designed for RT-PCR based on the previous study (Nozawa et al., 
2009). To recognize the trpa1 channel 5′-TCCTATACTGGAAGCAGCGA-3′, and 5′-
CTCCTGATTGCCATCGACT-3′; 18S was used as an internal control 5′-
CGGCTACCACATCCAAGGAA-3′ and 5′-GCTGGAATTACCGCGGCT-3′. The 
accumulation of PCR products were measured by the level of iQ™SYBR Green 
Supermix (BIO-RAD, 170-8880, USA) fluorescence following manufacturer’s manual on 
a 7300 Read Time PCR System (Applied Biosystems). The interested gene expression 
level (trpa1) was normalized by the expression of 18s expression. Relative quantification 
was calculated as X = 2 – ΔΔCt, where ΔΔCt = ΔE−ΔCt and ΔE = Ct exp – Ct18s, ΔCt = 
Ct control – Ct 18s (Livak and Schmittgen, 2001). Data were then normalized to the 
average of the control groups. 
 
Dissociation of DRG cell and preparation 
 
Based on the previous study, the L3-L6 DRG cells were dissociated acutely (Ma 
and LaMotte, 2005). We collected DRG cells from sham control and SCI group 3 weeks 




for 20 min (1 mg/ml; Roche Applied Science, Indianapolis, IN), then treated by papain 
(30 U/ml, Worthington Biochemical, Lakewood, NJ) in HBSS containing 0.5 mM EDTA 
and cysteine at 35 °C. The cells were placed in culture media, which contains 1 mg/ml 
bovine serum albumin (BSA), trypsin inhibitor (Worthington Biochemical, Lakewood, 
NJ), Ham’s F-12 mixture and DMEM, 10% fetal bovine serum (FBS), penicillin and 
streptomycin (100 µg/ml and 100 U/ml) and N2 (Life Technologies). The cells were 
placed on coverslips which coated with poly-L lysine and laminin (BD Biosciences) and 
incubated for 2-3 hours, then additional culture media was provided to the wells. Cells 
were cultured for 12-15 hours at 37°C with 5% CO2.  
 
Intracellular Ca2+ imaging 
 
To investigate the intracellular Ca2+ imaging, DRG cells were in a balanced sterile 
salt solution (BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), 
glucose (10 mM), KCl (5 mM)] for 25 min at room temperature with Fura-2 AM (3 µM, 
Molecular Probes/Invitrogen Corporation, Carlsbad, CA). After rinsing with the BBS, the 
cells were placed onto the inverted microscope chamber. MetaFluor software (Molecular 
Devices Corporation, Downington, PA) and digital video microfluorometry with an 
intensified CCD camera coupled to a microscope were used for measuring Intracellular 
calcium level. We selected the Fura-2 (340/380 nm) excitation wavelengths by a filter 
changer, and a 150W xeonnon arc lamp were used for cell illumination. Before adding 
acrolein, sterile solution was added to the cells, and if cell responded to buffer only, this 
cell was not used for neuronal responsive counts. It there was no response to buffer alone, 
250 µM of acrolein was applied into the coverslip directly. We waited for 2 min then 
washed out acrolein solution, if there was no response. After washing out acrolein, 3 μM 










Electrophysiology data recoding were performed 12-18 hours after cell 
dissociation. DRG-contained coverslips were move to a recoding chamber which is on 
the stage of an inverted microscope (Nikon Eclipse Ti, Nikon Instruments Inc., Melville, 
NY). A bath solution (NaCl 120mM, KCl 3mM, CaCl2 1mM, MgCl2 1mM, Hepes 
10mM, Glucose 10mM) was used for chamber perfusion, and adjusted to a pH 7.4 with 
an osmolarity of 300 mosM. All electrophysiology data were obtained at room 
temperature. Electrodes for intracellular recording were made from borosilicate glass 
(World Precision Instruments, Sarasota, FL) and pulled on a Flaming/Brown micropipette 
puller (P-98, Sutter Instruments, Novato, CA). Then, filling with 1.0 M KCl (impedance: 
40-80 MΩ), electrodes were positioned by a micromanipulator (Newport Corporation, 
Irvine, CA). For bridge-balance the electrode resistance, we used -0.1 nA current 
injection. The small (≤ 30 µm), medium (31–45 µm) and large (≥ 45 µm) diameter 
neurons were used for electrophysiological recordings with continuous current cpamp in 
bridge mode using an AxoClamp-2B amplifier, stored digitally via Digidata 1322A 
interface, and analyzed offline with pClamp 9 software (Axon Instruments, Union City, 
CA). The neuronal cells that showing a resting membrane potential (RMP) more negative 
than -45 mV were considered to be a positive data. For the isolated neuron studies, we 
used a continuous recording for 1 min without any stimulus. Action potential data were 
obtained by injecting current steps of 1 sec duration via the intracellular recoding 
electrode with 0.1 nA increase. This was maintained until generating one or more action 
potentials, or reaching 2 nA.  
 
The current threshold, which is the minimum injected to evoke a single action 
potential was assessed to investigated the effect of SCI itself. During the test, if there is 
spontaneous discharge, the sensory neuron was considered as spontaneous activity. To 
measure the excitability from small and medium diameter sensory neurons, 1s current 
pulses were injected into the soma every 30 sec. Current was adjusted for eliciting 3-4 




added to the coverslip after three control current injections, which was continued every 
30 sec. We measured the neuronal excitability by comparing the number of action 




One-way ANOVA was used to identify the source of significant interactions at 
each time point, followed by Tukey post hoc tests. For comparing only two conditions, 
The Student T-test was used. Yates-corrected chi-square test was used for differences in 
the incidence of neurons responding to acrolein. For the RT-PCR data analysis, un-paired 
t-test was used. All statistical analyses were performed using IBM-SPSS Statistics 
version 19.0 (SPSS inc., an IBM company, Chicago, IL, USA). P < 0.05 was considered 




Persistent elevation of acrolein protein level after traumatic SCI 
 
The acrolein-lysine expression level was measured by using immunoblotting 
(Figure 16). We collected about 1 cm of spinal cord tissue including damage site from 
animals 1 day after and 2 weeks after SCI. Acrolein-lysine expression level in spinal cord 
was significantly increased at both 1 day and 2 weeks after SCI. Specifically, the 
acrolein-lysine level in 1 day after SCI was 39.43 ± 2.46 and that in 2 weeks after SCI 
was 30.38 ± 2.71, while sham control group showed 9.68 ± 4.67, P < 0.001. This data 
supported that acrolein-lysine adducts level was persisted at least 2 weeks after SCI, 








TRPA1 mRNA gene expression level in the DRG after SCI 
 
To investigate the potential effect of acrolein on generation of neuropathic pain 
after SCI, we measured TRPA1 mRNA expression level via Real Time PCR (RT-PCR). 
For this study, we collected L1-L6 DRG cells from sham control and SCI 1 week after 
SCI (Figure 17). The data showed that TRPA1 mRNA level was significantly increased 
in DRG cells (2.03±0.11 fold) compared to the sham control group in 1 week after SCI. 
This data demonstrated that SCI could affect the expression level of TRPA1 channel, 
which may be related to increased-acrolein level. 
 
Increase of [Ca2+]i in DRG sensory cells by acrolein after SCI 
 
We have demonstrated that there were increase in acrolein level in spinal cord 
tissue and TRPA1 gene expression level SCI. Next, we investigated whether the 
exogenous acrolein can induce the increase of intracellular calcium level in DRG cells, 
which were collected from sham and SCI animals (Figure 18). The data indicated that 
about 38% of DRG sensory cells from sham control responded to acrolein alone, while 
about 14% of DRG cell from sham control responded to capsaicin and acrolein mixture. 
However, the percentage of DRG sensory cells that responded to acrolein from SCI 
groups was 58% (54/93) this was significantly higher than that in sham group (P < 0.005, 
Chi-square with Yates correction). There was no change in percentage of cell that 
responded to acrolein and capsaicin mixture compared to those in sham control group 
(17%). In addition, there was no change in the number of cells that responded to the 
capsaicin alone between sham control group (31%, 32/103) and SCI group (28%, 26/93 p 
> 0.05). This data demonstrated that, after SCI, there was an increased number of DRG 















Figure 16. Elevation of Acrolein-Lysine Adduct Level after SCI 
 
Immunodotblotting data indicated that SCI could result in the increase of acrolein-lysine 
adduct level in the spinal cord both 1 day and 2 weeks after SCI. Even though the 
acrolein-lysine level reached the highest points 1 day after SCI, its expression level was 
persisted 2 weeks after SCI. The acrolein-lysine adduct levels were 9.68 ± 4.67, 39.43 ± 
2.46, and 30.38 ± 2.71 in sham, 1 day after SCI, and 2 weeks after SCI respectively. All 
















Figure 17. TRPA1 Gene Expression Level in DRG Cells 
 
Relative TRPA1 gene expression level was quantified by using RT-PCR. We collected 
L1-L6 DRG cells 1 week after SCI. The interested gene level was normalized by the 
expression level of internal control (18s) and compared to the cycle threshold (Ct) value 
of 18s. This data indicated that there was about two folds increase in TRPA1 gene 
expression level in DRG cells from SCI. Paired t-test was used for the statistical analysis 














Figure 18. Calcium Imaging of TRPA1 Signaling via Acrolein in DRG 
 
A). Representative recording of a transient intracellular calcium increase in a DRG 
sensory neuron dissociated from a rat, following SCI, in response to acrolein (250 µM).  
The cells were loaded with Fura-2 (3 µM, Molecular Probes/Invitrogen Corporation, 
Carlsbad, CA). Intracellular calcium was measured by digital video microfluorometry. B). 
Calcium imaging data indicating the percentage of neurons that respond to acrolein and 
capsaicin with an intracellular calcium flux in naive and SCI dissociated DRG sensory 
neurons.  Following acrolein application, capsaicin (TRPV1 agonist) was added to further 
characterize the imaged cells as nociceptive neurons.  In naïve rats, 38% of neurons 
exhibited an acrolein-induced [Ca2+]i flux (n=103) where approximately one third of the 
neurons also exhibited a capsaicin-induced [Ca2+]i flux (36%). In rats that were 
subjected to SCI, a large percentage of neurons displayed an acrolein-induced [Ca2+]i 
flux (58%, n=93). This is significantly higher than what is observed in naïve rats (∗ P < 
0.005, Chi-square with Yates correction).  Among the SCI rats that responded to acrolein, 
29% of them also exhibited a capsaicin-induced [Ca2+]i influx.  Therefore, the proportion 





SCI can decrease the current thresholds in DRG sensory neurons  
 
Next, we tested if SCI itself can affect the sensory neuron’s activation state. For 
the Electrophysiological current clamp recordings, we used DRG cells from SCI and 
sham control group (Figure 19). To get the current threshold (CT), the minimum current 
was injected to evoke single action potential. The amount of current to generate single 
action potential in small diameter sensory neurons from SCI group was significantly 
lower than that in sham control group. It were specifically 0.9 ± 0.1 nA for sham injury 
and 0.4 ± 0.1 nA for SCI (p<0.05). In addition, medium diameter from SCI group also 
showed a significantly reduced amount of current that was needed to generate single 
action potential compared to DRG sensory neurons from sham control group (1.1 ± 0.1 
nA for sham injury vs. 0.6 ± 0.1 nA for SCI, p<0.05). However, there were no differences 
in amount of current using large diameter of sensory neurons between SCI and sham 
control group. Specifically, the mean current threshold for large DRG neurons for SCI 
group was 2.10 ± 0.33 nA (n = 15) and 1.99 ± 0.17 nA for sham-injury animals (n =20). 
This data demonstrated that SCI alone can change and increase the overall state of small 
and medium diameter sensory neurons.  
  
Increased excitability of DRG neuron after a combination of SCI and 
acrolein. 
 
Through this study, we have demonstrated that there were an increased number of 
cells that responded to acrolein after SCI, and SCI alone could reduce the current 
threshold to evoke single action potential in DRG sensory neuron. This time, we 
investigated whether the acrolein could increase the sensitivity of single sensory neuron. 
For this test, we collected DRG cells from sham control and SCI group. We tested 
sensory cells’ response using sharp electrodes in current clamp mode to investigate the 
degree to which acrolein could induce the excitability in single sensory neuron level. 
During the study, acrolein did not induce the spontaneous activity in all tested neurons. 




neurons when compared with baseline levels in DRG sensory neurons from sham control 
and SCI group, after combination of repeated current injections with acrolein adding 
(Figure 20). Specifically, the mean number of action potential by injecting minimum 
current in sensory neuron from sham control group was 1.9 ± 0.1 APs (n=12) for control 
and 4.7 ± 1.0 APs following acrolein application (n=3) (Figure 20B). However, the 
average number of action potentials which can be generated minimal current injection in 
sensory neuron from SCI group was 2.3 ± 0.4 APs for control (n=14) and 8.0 ± 0.9 APs 
after adding acrolein (n=5) (Figure 20B). In both sham control and SCI group, 
application of acrolein could increase the sensory neurons’ excitability compared to 
controls (p<0.05). Furthermore, the increased excitability by acrolein in sensory neuron 
was greater in SCI group compared with sham control (Figure 20B). This data indicated 
that acrolein could increase the neuronal cells’ sensitivity, and acrolein-mediated 



























Figure 19. SCI-mediated Current Threshold to Generate Action Potential 
 
SCI alone can decrease the current threshold (CT), which is minimal current to generate 
single action potential in small and medium diameter sensory neurons. Lumbar DRG 
cells from sham and SCI group were used for current clamp recording. A). CT value in 
small diameter sensory neuron was reduced in SCI compared to DRG cells from sham 
group (A2 vs. A1). The current threshold was 0.9 ± 0.1 nA for sham injury and 0.4 ± 0.1 
nA for SCI, p<0.05 (B). C) CT value in medium sensory neuron also decreased following 
SCI (C1 vs. C2). Specifically, amount of injected current was 1.1 ± 0.1 nA for sham 
injury and 0.6 ± 0.1 nA for SCI, p<0.05. There was no difference in CT using large 
diameter of sensory neuron between sham and SCI group. The number means the number 

















Figure 20. Acrolein-Induced Sensory Neuron’s Excitability after SCI. 
 
The number of action potentials by injected minimal current was measured to investigate 
the acrolein-mediated excitability 2 weeks after SCI. We used small and medium 
diameter of DRG cell from L3-L6 for the current clamp recordings. Using a 1 second 
depolarizing current injection (ranging from 0.1 to 2.0 nA depending on the cell) every 
30 seconds, two or four action potentials were generated. A) Representative recording for 
application of 250 µM acrolein could increase the number of generation of action 
potentials in DRG sensory neurons from SCI group. B) Acrolein application can 
significantly increase the DRG neurons’ excitability in both sham control and SCI group 
(n=12 for sham injury controls, and n=14 for SCI controls, ANOVA *p<0.05,). 












Micro-injected acrolein into the spinal cord produces neuropathic pain 
behavior. 
 
We investigated whether the acrolein alone could generate the neuropathic pain-
like behavior without any mechanical injury. We injected a small amount of acrolein into 
the rat’s spinal cord dorsal horn directly on animal’s right side of spinal cord. For the 
control, the same amount of saline was injected on the left side of spinal cord. The data 
showed that micro-injected acrolein into the spinal cord could produce the mechanical 
allodynia and cold allodynia on the side of injection site (Figure 21). However, 
application of saline to the contralateral side did not show any specific neuropathic pain 
behaviors.  
 
Hydralazine can attenuate the neuropathic pain behavior after SCI 
 
Next, we tested the analgesic effects of acrolein scavenger hydralazine following 
SCI. 5mg/kg of hydralazine was injected via I.P injection everyday for two weeks. The 
results data showed that hydralazine could significantly alleviate the mechanical and cold 
allodynia compared to hydralazine non-treatment group during the experiment period 
(Figure 22A and 22B). Furthermore, the acrolein-lysine adduct level was significantly 
decreased in hydralazine treatment group when compared to the SCI only group (Figure 
22C, p<0.05). This data demonstrated that acrolein scavenger hydralazine could attenuate 
neuropathic pain behaviors after SCI via acrolein scavenging way.  
 
Delayed application of hydralazine reduces neuropathic pain after SCI 
 
So far, to investigate the analgesic effect of hydralazine, we have injected 
hydralazine right after SCI within 5 min. However, clinically, applying medication right 
after SCI is impossible. In this sense, we tested whether the delayed application of 
acrolein scavenger hydralazine could attenuate neuropathic pain behaviors after SCI. So, 




then we did mechanical and cold allodynia tests every week until 7 weeks after SCI. The 
data indicated that the delayed beneficial effects of hydralazine also altered neuropathic 
pain behaviors after SCI (Figure 23A). This treatment paradigm significantly attenuate 
mechanical allodynia from 35 days to the end of period (p<0.05), and cold allodynia from 




































Figure 21. Micro-injected Acrolein Produced Neuropathic Pain Behaviors  
 
The same amount of acrolein (40nmol, 1.6 µL) and saline (1.6 µL) was injected into the 
spinal cord directly, which could change the responses to mechanical and cold stimulus. 
A) Mechanical threshold in acrolein injection side significantly lower than that in saline 
injection side up to 10 days. B) Withdrawal frequency to 100% acetone also significantly 
increase compared to saline injection side. These data showed that acrolein alone could 
induce the neuropathic pain behaviors without any traumatic damage to the spinal cord. 
One way ANOVA and Tukey’s test were used for statistical analysis.  (∗ P < 0.05 when 


















Figure 22. The Effect of Hydralazine on Pain Behaviors and Acrolein Level after 
SCI 
 
A and B) Daily application of hydralazine for two weeks could attenuate the SCI-induced 
neuropathic pain mechanical and cold allodynia. On days from 14 to 28 after SCI, only 
SCI group was sensitive to mechanical and cold stimulus compared to sham control and 
SCI treatment with hydralazine (# P < 0.05 when compared to the sham injured control 
and ∗ P < 0.05 when compared to SCI alone). C) Acrolein-lysine adduct level was 
significantly reduced by acrolein scavenger hydralazine in one day after SCI. (n=6 in 
each condition).  (∗P < 0.05, ∗∗P < 0.01, ANOVA).  All data (A-C) were expressed in 















Figure 23. Delayed Application of Hydralazine on Neuropathic Pain after SCI 
 
To investigate the effect of delayed application of hydralazine, 5mg/kg of hydralazine 
was injected 2 weeks after SCI for 5 weeks every day. Mechanical and cold allodynia 
were assessed weekly until 49 days after SCI. A) The mechanical threshold in 
hydralazine treatment group significantly lower than SCI only at 35 days after SCI until 
49 days after SCI. B) Like mechanical allodynia, withdrawal frequency to acetone in 
hydralazine treatment group was significantly higher than that in SCI only at 21 days 
after SCI. These data showed that delayed application of hydralazine also attenuated SCI-
induced hypersensitivity. (∗ P < 0.05 when compared to SCI group, n=4 for all groups).  












3.4 Discussion  
 
This study has demonstrated that SCI-injuced acrolein level could be persisted at 
least two weeks at the damaged spinal cord tissue. This SCI-induced generation of 
acrolein correlated with the onset of neuropathic pain mechanical and cold allodynia. In 
addition, our data demonstrated that SCI could induce a reduction of current threshold to 
generate action potential and an increase in the number of DRG sensory cells that 
responded to acrolein. In addition, exogenously injected acrolein into the spinal cord 
could produce the neuropathic pain mechanical and cold allodynia without any traumatic 
mechanical damage to the spinal cord. Furthermore, application of acrolein to DRG 
sensory neurons could increase the excitability of small and medium diameter of sensory 
neurons following SCI. Taken together, these data strongly support that SCI-induced 
acrolein plays a critical role in generation of neuropathic pain behavior as a pro-
nociceptive factor.  
 
Through this study, we observed increased level of acrolein after SCI may 
implicate in generation of neuropathic pain by increasing sensory neurons’ excitability in 
lumbar level of DRG. Because of acrolein’s nature such as diffusion cross membrane and 
circulation through the system, elevated acrolein in thoracic level of spinal cord could 
spread out throughout the spinal cord via subarachnoid space (Luo et al., 2005b). In 
addition because of the permeability of the DRG cells, SCI-induced acrolein could 
directly increase the sensitivity of sensory neurons (Devor, 1999; Abram et al., 2006; 
Puljak et al., 2009).  
 
As a pro-nociceptive factor, acrolein can induce an increase of influx of calcium 
ion into the cell through TRPA1, which can also activate phospholipase C (PLC) signal 
transduction (Bautista et al., 2006; Dai et al., 2007). TRPA1 channel can also promote the 
pain sensitivity through other stimuli (Lennertz et al., 2012; Zhao et al., 2012; Perin-





There is little information about the changes in TRP channel’s expression level 
after SCI. Our data showed that there was an increase in the expression level of TRPA1 
gene after SCI. In this sense, TRPA1 channel could be a potential target for analgesic 
medication. According to previous studies, TRPA1 antagonists could be applied as an 
effective analgesic by blocking the pain transmission (Eid et al., 2008; Andre et al., 2009; 
Bessac et al., 2009; Kerstein et al., 2009). However, TRPA1 antagonists for SCI-induced 
neuropathic pain as analgesic remained uncertain and many of these antagonists are 
needed to be studied further for clinical application.  
 
In this sense, as an endogenous TRPA1 agonist, acrolein could be a more reliable 
therapeutic target after SCI. Many of studies have shown that acrolein has been 
implicated in many types of neurodegenerative diseases by damaging to the CNS, 
proteins, lipids and DNA (Shi et al., 2002b; Hamann et al., 2008b; Leung et al., 2011c; 
Shi et al., 2011). With acrolein’s nature and as a pro-inflammatory factor, it can 
contribute to the generation of chronic neuropathic pain after SCI.  
 
The role of acrolein in generation of neuropathic pain was assessed with acrolein 
scavenger hydralazine. The data showed that systemic application of hydralazine after 
SCI could reduce not only the acrolein-lysine adduct level, but also neuropathic pain 
mechanical and cold allodynia. In addition, delayed application of hydralazine also 
showed its analgesic effect after SCI. However, we also need to consider about the role of 
hydralazine on nervous system. As the FDA approved hypertensive medication, 
hydralazine promotes the increase of cGMP level in smooth muscle resulting in 
relaxation of blood vessels. However, one previous study has demonstrated that cGMP-
PKG signaling pathway agonist could promote the sensory neuron’s excitability via in 
vitro experiments (Song et al., 2006; Zheng et al., 2007). Based on these results, there is a 
possibility that hydralazine application could also promote the neuropathic pain-like 
behaviors such as mechanical and cold allodynia in sham control group. But, we did not 





treatment groups. Therefore, an analgesic effect of hydralazine is correlated with 
scavenging of acrolein after SCI.  
 
There could be other TRP channels that respond to cold stimulus resulting in SCI-
induced neuropathic pain other than TRPA1. TRPM8 is the sub-family of TRP channels, 
which is activated by cold and cold effect-generated molecules such as menthol and icilin 
(McKemy et al., 2002; Patapoutian et al., 2003; Patapoutian et al., 2009). In addition, 
some of TRPA1 agonists have been shown to activate TRPM8 (Story et al., 2003). 
According to the previous studies, TRPM8 has been implicated in sciatic nerve injury-
induced sensitivity to cold stimulus and tissue inflammation (Colburn et al., 2007; 
Knowlton et al., 2010). However, recent studies have demonstrated that TRPM8 gene 
expression level in lumbar DRG cells in significantly lower than TRPA1 gene expression 
level under naïve conditions (Vandewauw et al., 2013). Furthermore, acrolein is known 
as TRPA1 specific agonist which support that the analgesic effect of hydralazine 
attenuates acrolein-induced neuropathic pain, which was mediated via TRPA1 not 
TRPM8.  
 
3.5 Conclusion  
 
Our data supports that acrolein can enhance the neuronal sensitivity after SCI, 
which is known as pro-nociceptive TRPA1 agonist and pro-inflammatory factor. With 
evidence that elevation of acrolein level after SCI until two weeks, acrolein could be a 
valuable therapeutic target for neuropathic pain. In addition, DRG neurons remain 
hypersensitivity to stimuli because of persistent up-regulation of TRPA1 channel level 
after SCI. In this sense, anti-acrolein strategy using hydralazine could be an effective way 
to attenuate not only the initial state (acute) of neuropathic pain, but the chronic stage of 
neuropathic pain following SCI.  
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CHAPTER 4. THE EFFECT OF TRPA1 CHANNEL IN THE PERIPHERAL 
TERMINAL AFTER SPINAL CORD INJURY 
4.1 Background and Research Scope of This Study 
 
Noxious mechanical and thermal stimuli can act on the peripheral terminals of 
primary sensory afferent nerve. The conversion of mechanical, chemical and thermal 
stimuli into electrical signal and signal transmission are conducted by transient receptor 
potential (TRP) channels (Puljak et al., 2009). Basically, TRPs are non-selective cation 
calcium ion permeable channels which comprise six transmembrane segments (S1-S6) 
and ion permeable pore is located between S5-S6 (Bandell et al., 2007; Nilius et al., 2012; 
Bautista et al., 2013).  
 
The transient receptor potential ankyrin 1 (TRPA1) channel is a member of the 
TRP channel family and also calcium permeable non-specific cation channel. As the only 
TRPA subfamily member, TRPA1 channels are expressed in both neuronal cells such as 
unmyelinated primary sensory neuron C fiber, DRG cell body and trigeminal ganglia 
neurons and non-neuronal tissues such as respiratory tract, gastrointestinal tract, bladder, 
and keratinocytes (Patapoutian and Macpherson, 2006; Patapoutian et al., 2009; Nilius et 
al., 2012; Bautista et al., 2013). Based on channel’s ability to respond to noxious stimulus, 
pain sensing channels can be divided into unimodal, which are activated by a unique 
stimulus and polymodal, which are stimulated by various stimulus such as environmental 
irritants, mechanical, and thermal stimuli (Dhaka et al., 2006). TRPA1 channels are 
activated in a polymodal fashions. That is, TRPA1 can be activated by environmental 
irritants (acrolein), thermal sensation (cold), pro-inflammatory factors (bradykinin) and 




are located in the intracellular part. Specifically, the long ankyrin-repeated domain at N-
terminal plays a critical role for activation of TRPA1 channel. EF-hand motif on ankyrin-
repeated domain where calcium ion can bind to and activate TRPA1 channel, and cystein 
and lysine neucleophilic amino acid on here, which are the targets for electrophilic 
TRPA1 agonists contribute to gate the TRPA1 channel as well (Clapham et al., 2001; 
Bandell et al., 2007).  
 
According to the previous study, TRPA1 channel is known for endogenous 
byproducts of oxidative stress process such as lipid peroxidation (LPO) (Andersson et al., 
2008). Byproduct of LPO after neuronal damage, acrolein is known as TRPA1 specific 
agonist because of its electrophilic properties. With these properties, β-carbon of the a,β-
unsaturated aldehyde, acrolein can bind to nucleophilic thiol group of cystein and ε-
animo group of lysine residues via covalent modification. Especially, reaction between 
acrolein and cystein is reversible, so acrolein can break from acrolein-cystein adduct and 
react with other proteins and DNA (Hinman et al., 2006; Bandell et al., 2007; Nilius et al., 
2007; Andrade et al., 2008; Andre et al., 2009; Patapoutian et al., 2009). This covalent 
modification between TRPA1 channel and electrophiles contribute to gate of TRPA1 
channel and transmit pain signaling.  
 
TRPA1 channels are also activated by non-electrophile agonists G-protein coupled 
receptor indirect pathway (Bautista et al., 2005; Bautista et al., 2006). Bradykinin (BK) is 
known as pro-inflammatory factor. When it binds to its receptor bradykinin 2 receptor 
(B2R), it can activate phospholipase C (PLC) signaling and promote the release of 
calcium ions from intracellular calcium store. Released-calcium ions can bind to EF-hand 
domain which is located on N-terminal of TRPA1 activate TRPA1 channel. Acrolein is 
also known as pro-inflammatory factor (Bautista et al., 2006). As an inflammatory factor, 
acrolein has been shown to stimulate the release of chemokines such as monocyte 
chemotactic protein-1 (MCP-1 or CCL2) (Knerlich-Lukoschus et al., 2008; Knerlich-
Lukoschus et al., 2011). In the nervous system, MCP-1 is expressed in nociceptive 




Abbadie et al., 2009). In addition, MCP-1 is released at the postsynaptic spinal dorsal 
horn to promote the activity of neuronal glial cells that express MCP-1 receptor CCR2 
(White et al., 2005; White et al., 2009). Based on previous study, acrolein-induced MCP-
1 and CCR2 activation can result in induce the neuropathic pain-like behaviors through 
transactivation of TRPA1 channel (Knerlich-Lukoschus et al., 2010). In this sense, with 
acrolein’s diffusive nature, stable and prolonged presence in the body, acrolein can serve 
as a pro-inflammatory factor that contributes to generation of chronic neuropathic pain 
after SCI by either directly or indirectly. 
 
TRPA1 pore which is located between S5-S6 is stimulus dependent. Under the 
neuropathic pain condition, it has a wide size of pore compared to normal physiological 
condition, which induces the large number of calcium ion influx  (Patapoutian and 
Macpherson, 2006; Bandell et al., 2007; Patapoutian et al., 2009; Nilius et al., 2012). In 
chapter 3, we have demonstrated that the expression level of TRPA1 mRNA was 
increased in the DRG after SCI. Based on this result, we can speculate that pain can 
promote not only the TRPA1 channel expression, but also the pore size of TRPA1 
channel. As we already mentioned above, TRPA1 channels are expressed on nociceptive 
C fiber, specifically, peptidergic primary afferent neuron. So, when TRPA1 channels are 
activated, they can activate the releases of nociceptive neurotransmitters such as 
substance P and glutamate to higher order sensory neurons (Bautista et al., 2006; 
Macpherson et al., 2007). In this sense, TRPA1 channels on the central ending of primary 
afferent neurons in the spinal dorsal horn may play a critical role in the generation and 
maintenance of pain signaling. However, there is little information about the role of 
TRPA1 channels on the peripheral terminal of primary afferent sensory fiber. Therefore, 
main goals of this study are to demonstrate the role and effect of TRPA1 channels in the 
peripheral terminal of primary afferent nerve after SCI, and to investigate the effect of 
acrolein after SCI whether it can promote the increase of sensitivity of responsiveness at 
the peripheral terminal nerve. Lastly, we will investigate that the scavenging strategy 
using acrolein scavenger hydralazine to check whether hydralazine treatment could 




horn of spinal cord and paw skin at 1 week and 2 weeks after SCI, and attenuate the 
neuropathic pain behavior after SCI.  
 
In this study, we assessed the involvement of acroelin in neuropathic pain after SCI 
by using immunoblotting and urine 3-HPMA techniques and investigated the effect of 
TRPA1 channels on peripheral terminal of a primary afferent nerve after SCI by using 
RT-PCR with various tissues and time points.  
 
4.2 Spinal Cord Injury-induced Neuropathic Pain Mechanical Allodynia 
 
Through chapter 2 and 3, we have demonstrated that spinal cord injury could lead 
to neuropathic pain behaviors. Here we again confirmed that NYU impactor induced 
contusion injury at spinal cord T-10 level resulted in neuropathic pain mechanical 
allodynia (figure 24). 2 weeks after SCI, the mechanical threshold in SCI group was 



























Figure 24. Mechanical Sensory Hypersensitivity after Moderate Contusive SCI 
 
Mechanical sensory status was determined using Von Frey filament performed before the 
injury, and weekly post injury starting two weeks post SCI for up to 5 weeks. Note that 
there were no difference in mechanical threshold in sham injury and SCI groups before 
the injury. However, starting from 14 days post injury, the average values of the 
mechanical threshold in SCI group were significantly reduced compared to sham group in 
the 2-5 weeks post SCI. N=10~13 in each group. **P < 0.01. One-way ANOVA and 













4.3 Changes in TRPA1 Gene Expression Level after SCI 
 
In chapter 3, we have demonstrated that there was increased in TRPA mRNA gene 
expression level in lumbar level of DRG 1 week after SCI. In this chapter, we assessed 
TRPA1 gene expression level with various tissues such as DRG, dorsal horn of spinal 
cord and hind limb paw skin in 1 week and 2 weeks after SCI. For the RT-PCR, we 
collected L1-L6 DRG cells, dorsal horn of spinal cord including T-10 injury site, and 
hind-limb paw skin from sham control group and SCI group. As the result is shown in 
figure 25, the TRPA1 gene expression level was significantly increased in all tissues at 1 
week and 2 weeks after SCI, however, there was no difference between 1 week and 2 
weeks after SCI in dorsal horn of spinal cord, DRG, and paw skin. Specifically, TRPA1 
gene expression level in spinal dorsal horn was 2.58±0.16 for 1 week and 2.57±0.43 for 2 
weeks after SCI (p>0.05), in DRG (2.03±0.22 vs 1.87±0.21, p>0.05), and in paw skin 
(41.45±2.99 vs 38.48±2.02, p>0.05). This data indicated that TRPA1 gene level could be 
persisted at least 2 weeks after SCI.  
 
Next, 5mg/kg of acrolein scavenger was injected for 1 week and 2 weeks after SCI 
daily to investigate the benefits of hydralazine on reduction of TRPA1 channel gene 
expression level in various tissues after SCI. Figure 26 showed the gene expression level 
1 week after SCI in dorsal horn, DRG, and paw skin. The data indicated that systemic 
application of hydralazine could attenuate gene expression level in all tissues. 
Specifically, the gene expression level induction folds were reduced from 2.6±0.15 to 
1.0±0.13 in dorsal horn of spinal cord, from 2.0±0.22 to 1.2±0.20 in DRG, and from 
41.4±2.98 to 0.60±0.11 in hind limb paw skin. Furthermore, figure 27 showed that even 2 
weeks after SCI, TRPA1 levels in SCI group were significantly higher than those in sham 
control. Specifically, Gene expression level 2 weeks after SCI were significantly 
increased in dorsal horn (2.57±0.45), DRG (1.27±0.22) and paw skin (38.48±2.0) 
following SCI. However, acrolein hydralazine could significantly reduce the TRPA1 
gene expression level dorsal horn (0.71±0.10), DRG (0.59±0.01) and paw skin 




HPMA results, acrolein was involved in an increase in TRPA1 gene expression level in 
both peripheral and central terminal of a primary afferent nerve especially, SCI could 
contribute to the increase in expression level of TRPA1 at the peripheral terminal of 
primary sensory neurons. In addition, as a TRPA1 channel specific agonist, acrolein 


































Figure 25. The Elevation of TRPA1 mRNA Level 1 Week and 2 Weeks after SCI 
 
Bar graph indicates the RT-PCR relative quantification of TRPA1 mRNA examined 1 
and 2 weeks post SCI at three tissue types: Dorsal horn (1 cm long including T10), DRG 
(L1-L6), and paw skin (1 cm x 1cm).  Gene expression was normalized by the expression 
of 18 s and compared to the cycle threshold value for 18 s of tissue mRNA post SCI. 
There was no difference of RT-PCR mRNA level of TRPA1 between two time points (1 
week vs 2 weeks) in each tissue type.  However, significant difference were detected 
regarding the RT-PCR mRNA level of TRPA1 between SCI and sham group in three 
tissue types at both 1 week and three week.   Note near forty fold increase of TRPA1 
mRNA in paw skin presented 1 and 2 weeks post SCI. ∗ P < 0.05, ∗∗∗ P < 0.005  when 
compared to sham. One-way ANOVA and Tukey test.  All values were expressed as 














Figure 26. The Effect of Hydralazein on TRPA1 mRNA Level 7 Days after SCI 
 
The suppression of TRPA1 mRNA level by acrolein scavenger hydralazine in spinal 
dorsal horn (1 cm long including T10), dorsal root ganglia (DRG, L1-L6), and paw skin 
assessed 7 days after SCI. Specifically, the TRPA1 mRNA levels were significantly 
increased in dorsal horn, DRG, and paw skin following SCI (P < 0.05 in dorsal horn and 
DRG, and P < 0.001 in paw skin group when compared to sham).  However, this elevated 
TRPA1 mRNA was significantly attenuated in all three tissue types with the continuous 
daily IP injection of hydralazine for a week post SCI. (∗ P<0.05, ∗∗∗ P<0.005 when 
compared to SCI alone, One-way ANOVA and Tukey test).  N=4~8 in each group. All 














Figure 27. The Effect of Hydralazein on TRPA1 mRNA Level 14 Days after SCI. 
 
The suppression of TRPA1 mRNA level by acrolein scavenger hydralazine in spinal 
dorsal horn (1 cm long including T10), dorsal root ganglia (DRG L1-L6), and paw skin 
assessed 2 weeks after SCI. Specifically, the TRPA1 mRNA levels were significantly 
increased 14 days post SCI in dorsal horn, DRG, and paw skin following SCI (P < 0.05 in 
dorsal horn, DRG, and P < 0.001 in paw skin group when compared to sham).  However, 
this elevated TRPA1 mRNA was significantly attenuated in all three tissue types with the 
continuous daily IP injection of hydralazine for 2 weeks post SCI. (∗ P<0.05, One-way 
ANOVA and Tukey test).  N=4~8 in each group. All values were expressed as mean 









4.4 Persistent Elevation of Acrolein Level and Onset of Neuropathic Pain 
Behaviors after SCI  
 
Through chapters 2 and 3, we have shown that there were elevated level of acrolein 
and acrolein metabolite 3-HPMA level after SCI. In addition, we have demonstrated that 
as a pro-nociceptive factor acrolein may correlate with onset of neuropathic pain 
mechanical and cold allodynia and enhance neuronal sensitization after SCI. Furthermore, 
when we treated with acrolein scavenger hydalazine, it could not only attenuate acrolein-
lysine adduct level and neuropathic pain mechanical and cold allodynia, but also promote 
locomotor functional recovery following SCI. These data indicated that considering 
neurotoxicity of acrolein, anti-acrolein therapy could be an effective treatment to alleviate 
neurological deficits and enhance functional recovery for SCI patients. Here, we again 
confirmed our theory by measuring acrolein level via immunoblotting, urine 3-HPMA 


























Figure 28. Elevation of Acroein-lysine Adducts in Spinal Cord  
and 3-HPMA after SCI. 
 
A) Bar graph depicts the elevation of acrolein-lysine adduct level in spinal cord tissue 
after contusive spinal cord injury (SCI) at 1 day and 2 weeks post injury. Measurements 
through dot immunoblotting indicated that SCI was associated with significant elevation 
of acrolein-lysine adduct 1 day following SCI compared to sham injury group. Persistent 
elevations of acrolein-lysine adduct were observed for at least 2 weeks after SCI.  Top: 
photograph shows a representative blot for each conditions.  Bottom: Bar graph depicts 
the quantification of the bands density by Image J.  N=6~8 for each group. ∗ P < 0.05, ∗∗ 
P < 0.01. One-way ANOVA and Tukey test. B) Elevated level of 3-HPMA, an acrolein 
metabolite, in urine after SCI in rats (3.5 ± 0.24 μg/mg), when compared to sham injured 
group (1.9±0.21 μg/mg). Rat urine samples were collected one day after SCI to determine 
3-HPMA level. N=4~6 in each group. ∗P < 0.05. unpaired t-test. All values were 







4.5 Gene Expression Level and Behavioral Alternations by Pro-nociceptive Factor 
Acrolein  
 
In chapter 2 and 3, we have shown that acrolein alone could lead to neuronal tissue 
damage, motor and sensory function deficits without any traumatic damage to spinal cord. 
And also, the data indicated that SCI could result in the increase of TRPA1 mRNA 
expression level in spinal dorsal horn, DRG, and paw skin 1 week and 2 weeks after SCI.  
 
In this chapter, we investigated whether acrolein itself could promote the elevation 
of TRPA1 gene expression levels in dorsal horn of spinal cord, DRG, and paw skin 
without any traumatic injury. We also have tested if acrolein could promote generation of 
neurological deficits such as neuropathic pain and locomotor dysfunction. Initially, 
certain amount of acrolein (40nmol, 1.6 µl) was injected into the T-10 level of spinal cord 
directly which was the same location as we described in chapter 2. Again, same amount 
of saline was injected into the animals’ left side of spinal cord as a control. The gene 
expression level was assessed using RT-PCR and tissues samples were collected 1 week 
after acrolein injection. Figure 29 showed the result of relative TRPA1 mRNA gene 
expression level in DRG, spinal cord dorsal horn, and paw skin. As the data indicated, 
TRPA1 gene expression levels were significantly increased in all tissues 1 week after 
acrolein micro-injection. Specifically, the increased gene expression levels were 83.4±5.9 
folds (DRG), 56.9±8.4 folds (spinal dorsal horn) and 76.3±6.4 folds (paw skin). This data 
demonstrated that acrolein alone could result in elevation of TRPA1 gene expression 
level without any traumatic SCI. This data also further supported that acrolein played a 
critical role in an elevation of TRPA1 gene expression level in both peripheral and central 
terminal of a primary afferent nerve, and it could be the valuable therapeutic target for 














Figure 29. The Effect of Micro-Acrolein Injection on TRPA1 mRNA Level in 
Tissues 
 
Relative TRPA1 mRNA expression level was assessed in DRG, spinal dorsal horn and 
paw skin after direct injecting acrolein (40nmol, 1.6 µl) into spinal cord. For the control, 
the same amount of saline was injected into the animals left side of spinal cord. 
Compared to saline injection site, the gene expression levels were significantly increased 
in DRG (83.4±5.9), (spinal dorsal horn) 56.9±8.4, and (paw skin) 76.3±6.4 folds. This 
data indicated that acrolein could induce the gene expression level changes in the central 
and peripheral terminal of primary afferent without any traumatic mechanical injury. N=4 









Next, we tested, again, the ability of acrolein as a pro-nociceptive factor. This 
time, the experiment period has been extended from 10 days (in chapter 3) to 14 days. To 
examine the effect of acrolein on neuropathic pain generation, we performed mechanical 
and cold allodynia neuropathic pain tests after acrolein micro-injection every 2 days until 
14 days (Figure 30). As figure 30 indicated, acrolein micro-injection into the spinal cord 
promoted significant mechanical and cold hypersensitivity on the injection site, whereas 
saline injection to the contralateral side led to the decreased or absence of 
hypersensitivity response to mechanical and cold stimuli. Furthermore, micro-injected 
acrolein-induced neuropathic pain behaviors were maintained at least 2 weeks. This data 
supported that acrolein could generate the neuropathic pain mechanical and cold 
allodynia without any traumatic mechanical injury to the spinal cord.  
 
 In addition to the ability of acrolein on generation of sensory abnormalities, we 
tested if acrolein alone could promote the locomotor dysfunction without any mechanical 
injury. For this study, the experiment period also has been extended from 10 days (in 
chapter 2) to 14 days. We examined the animals’ locomotor ability of hind limb every 
two days for 14 days. As shown in figure 31, we found that the micro-injection of 
acrolein could produce significant locomotor malfunction on the side of acrolein injection, 
while there were little changes or a decreased in BBB score until first week, but it came 
back to normal BBB score (21) in 6 days after acrolein injection. This data suggested that 




















Figure 30. Micro-injected Acrolein Promoted the Mechanical and Cold Allodynia 
 
We tested if acrolein itself could generate neuropathic pain without any traumatic injury 
to the spinal cord. Using micro-pump device, 40nmol, 1.6 µl of acrolein was injected into 
the right side of spinal cord and the same amount of saline was used for a control into the 
left side of spinal cord at T-10 level. Micro-injected acrolein produced the significantly 
changes in withdrawal frequency to cold stimuli (A) and mechanical threshold (B). N=6 
in each group *P <0.05, **P<0.01 compared to control group. ANOVA and Tukey test 





















Figure 31. The Motor Function Deficits by Micro-injected Acrolein 
 
The changes of Basso, Beattie and Bresnahan (BBB) scores for acrolein (right, 40 nmol 
dissolved in 1.6 µL)) and saline (left) injections over the course of 2 weeks. Notice the 
significant reduction of the BBB score on the side of acrolein injection compared to the 
contralateral or saline injected side. **p < 0.01, *P < 0.05 for comparison between right 
side (acrolein injected) and left side (saline injected). One-way ANOVA then Tukey test.  










4.6 Acrolein Increases the Peripheral Terminal Sensitivity Following SCI 
 
Next, we have tested whether the acrolein could increase the peripheral terminal 
sensitivity following SCI. For this, initially, a volume of 25 µl of acrolein (625nmol) was 
injected into the intradermal plantar region of the right hind foot in sham control group 
and SCI group. Therefore, there were four different groups; group 1: normal rats, group 2: 
normal rats + acrolein injection, group 3: SCI rats, and group 4: SCI rats + acrolein 
injection. For the acrolein injection, a 30 gauge needle attached to a Hamilton Syringe 
was used (figure 32). A successful injection was considered if there was about 2 mm in 
diameter of bleb formation at the injection site and needle insertion site was pressed for 1 
min to prevent from leakage of acrolein solution after removal of the needle. An hour 
after acrolein injection, for the mechanical hypersensitivity test, animals were placed 
inside a plastic box. Mechanical threshold was measured using von Frey filaments up-
down method. As shown in figure 33A, peripherally injected acrolein resulted in the 
neuropathic pain-like behavior in control group. In addition, acrolein-mediated 
neuropathic pain behaviors were enhanced in SCI group (figure 33B). In both groups, 
intradermally injected acrolein contributed to the reduction of mechanical threshold from 
14.26±0.28 g to 10.65±1.22 g in control group (p<0.05), and from 5.42±0.41 g to 
0.82±0.24 g in SCI group (p<0.01). However, acrolein-mediated neuropathic pain effect 
was enhanced in SCI group. Specifically, the percentage of change of mechanical 
threshold after acrolein injection was 25.53±10.21% in sham control group and 
82.44±1.21% in SCI group (figure 33B). This data demonstrated that intradermally 
injected acrolein could generate neuropathic pain-like behavior in control group and 

















Figure 32. Sites for Acrolein Injection and Mechanical Allodynia Von Frey Test 
 
For the acrolein injection (25 µl, 625nmol), was injected using 30 gauge of needle. 
Initially, the needle was inserted at the site of A and solution was injected at the site of B. 





















Figure 33. The Effect of Peripheral Injection of Acrolein in Control and SCI group 
 
Peripheral paw injection of acrolein induced neuropathic pain-like behavior and its 
potentiation after SCI.  Mechanical sensitivity was assessed using Von Frey filament 
before and after the injection of acrolein at intraplantar paw. (A) Bar graph shows that 
mechanical threshold in both sham and SCI groups can be reduced significantly 
following acrolein injection (∗ P < 0.05, ∗∗ P < 0.01, when compared to pre-acrolein, 
One-way ANOVA then Tukey test). (B) The percent of change of mechanical threshold 
in SCI following acrolein injection was significantly greater compared that in sham group 











4.7 Summary and Discussion 
 
In this chapter, our data strongly supported that elevation of acrolein was correlated 
with establishment and maintenance of neuropathic pain after SCI. In addition, RT-PCR 
data showed that TRPA1 gene expression level could be persisted at least 2 weeks in the 
various tissues after SCI not only at the central ending of a primary sensory nerve (spinal 
dorsal horn), but also at peripheral terminal (paw skin) of a primary afferent. This data 
indicated that SCI can lead to the increase the gene expression level in the nervous 
system. However, when we treated SCI animals with acrolein scavenger hydralazine 
everyday, it could alleviate the expression level of TRPA1 gene in dorsal horn, DRG, and 
paw skin in 1 week and 2 weeks after SCI, which indicated that SCI-induced acrolein 
may contribute to the up-regulation of TRPA1 gene expression level in the nervous 
system after SCI. This is further supported by section 4.4. In here, micro-injected acrolein 
could up-regulate the gene expression level without any mechanical injury at the spinal 
cord. The data showed that the gene expression levels in acrolein injected side were 
significantly higher than that in saline injection side. Animal behavioral tests on acrolein 
micro-injected group also demonstrated that acrolein could lead to sensory and motor 
abnormalities with no mechanical damage. Taken together, acrolein, as a TRPA1 channel 
specific agonist, could be a promising therapeutic target for neuropathic pain treatment 
after SCI. 
 
Especially, out RT-PCR data indicated that increased TRPA1 gene expression level 
at the peripheral terminal of primary afferent nerve may contribute to the hypersensitivity 
to the stimuli after SCI. According to the previous studies (Nilius et al., 2007; Anand et 
al., 2008; Andre et al., 2009), TRPA1 channels were also expressed at the keratinocytes 
at the peripheral nerve. Our RT-PCR data figure 25, showed that the TRPA1 gene 
expression level in paw skin was much higher than that in any other tissues at 1 week and 
2 weeks after SCI (41.4±2.98 folds in skin, 2.6±0.15 folds in dorsal horn, and 2.0±0.22 in 
DRG at 1 week after SCI and 38.48±2.0 folds in paw skin, 2.57±0.45 folds in dorsal horn, 





pain mechanical and cold allodynia following SCI most likely due to the up-regulation of 
TRPA1 expression level in peripheral terminal of primary afferent sensory neurons. This 
is also further supported by two animal behavioral in vivo tests. First of all, as shown in 
figure 29, micro-injected acrolein directly into the spinal cord caused the up-regulation of 
TRPA1 gene expression level at the spinal dorsal horn, DRG, and skin. In addition, it 
induced neuropathic pain mechanical and cold allodynia. This acrolein-induced 
hypersensitivity to the mechanical and cold stimuli may be mainly caused by up-
regulation of TRPA1 gene expression at the peripheral terminal of primary sensory 
neurons. Secondly, data from figure 33 supported this theory. Figure 33 showed that 
acrolein intradermal injection could generate the neuropathic pain-like behavior in 
control animal group. However, acrolein-mediated neuropathic pain behaviors were 
enhanced in SCI in case of mechanical threshold. This behavioral phenomenon may be 
due to the increase of TRPA1 expression level at the peripheral ending of primary 


















CHAPTER 5. THE EFFECT OF PHENELZINE AS AN ALTERNATIVE TO A 
HYDRALAZINE 
5.1 Background and Research Scope of This Study 
 
The majority of researches on the acrolein scavengers have used the hydralazine, 
because its acrolein scavenging capacity was much greater than other well known 
aldehyde scavengers such as methoxyamine, aminoguanidine, pyridoxamine, and 
carnosine (Burcham et al., 2002; Burcham et al., 2004; Kaminskas et al., 2004b). 
Compared to hydralazine, the other acrolein scavengers such as phenelzine have less 
attention, even though it has also acrolein-scavenging capabilities (Burcham et al., 2002; 
Wood et al., 2006b).  
 
Through previous study, our in vitro experiment results have demonstrated that the 
ability of phenelzine to protect against acrolein-mediated cell death was very similar to 
that of hydralazine, and its protection capability seemed to increase with higher 
concentration. In addition, although there was no difference statistically between 
phenelzine and hydralazine, phenelzine could provide slightly better protection against 
free acrolein. Furthermore, cell viability data with phenelzine and hydralazine in 
uninjured cells demonstrated that phenelzine also provided the cellular protection through 
scavenging free radicals, which were produced by normal cells.  
 
Although hydralazine has benefits for acrolein scavenging, it has also some 
limitations for in vivo treatment. Basically, hydralazine is the FDA-approved 
hypertension medication, however, anti-hypertensive effect could be the life threatening 
side effect to, especially, SCI patients, which could cause the neurogenic shock. In this 




acrolein scavenger via in vitro experiment, anyone hasn’t evaluated the efficacy of 
acrolein scavenger phenelzine in SCI animal model. Therefore, the goal of these 
experiments is to investigate the efficacy of acrolein-scavenger phenelzine as an 
althernative to hydralazine at in vivo SCI animal model. 
 
5.2 Phenelzine Treatment Reduced 3-HPMA Production 
 
To investigate phenelzine as an acrolein scavenger, acrolein pre-incubated with 
saline (0.7 mg/kg), saline + acrolein + hydralazine (5mg/kg), and saline + acrolein + 
phenelzine (5mg/kg) were injected via I.P. For the acrolein scavenging, we waited for 60 
min before injecting solution to the animals and 24 hour after injection, we collected 
urine from animals. For the control group, only saline was injected. As indicated in figure 
34, such treatment significantly attenuated the 3-HPMA levels in urine. Specifically, the 
average urine 3-HPMA levels in control, acrolein + saline, acrolein + saline +hydralazine, 
and acrolein + saline + phenelzine were 2.06+0.06, 76.79±1.45, 6.84±0.23, and 
5.03±0.86 μg/mg respectively. This result showed that injection of acrolein containing 
acrolein scavengers such as hydralazine and phenelzine could reduce the level of 3-
HPMA in urine compared to the acrolein only group (p<0.001). This result clearly 
indicated that the reduction of 3-HPMA was correlated with acrolein scavenging by 
hydralazine and phenelzine. In addition, when we compared 3-HPMA levels in 
hydralazine and phenelzine treatment group, there was significantly difference between 
these groups. That is, the 3-HPMA level in phenelzine treatment group was significantly 
lower than that in hydralazine treatment group (p<0.05). Therefore, capability of 
















Figure 34. The Reduction of Urine 3-HPMA by Acrolein Scavengers 
 
For the 3-HPMA urine test, we collected urine 24 hours after I.P. injection. The 3-HPMA 
level in acrolein only injection group was significantly increased following injection. 
However, the elevated 3-HPMA level was decreased by more than 90% (from 
76.79±1.45 to 6.84±0.23, and from76.79±1.45 to 5.03±0.86 μg/mg). (# P < 0.001 when 









5.3 Acrolein Scavenging by Phenelzine after SCI 
 
To investigate the efficacy of phenelzine as an acrolein scavenger after SCI, we 
performed immunoblotting to measure the endogenous acrolein-lysine adduct level, and 
LC/MS/MS to detect acrolein metabolite urine 3-HPMA following SCI. First of all, we 
generated moderate SCI animal models using NYU impactor by dropping its weight rod 
from 25mm onto the intact spinal cord at T-10 level. Then, 5mg/kg of phenelzine was 
injected via I.P right after SCI within 3 min. Phenelzine solution was injected 2 times 
before euthanizing animals and 1 cm of spinal cord including T-10 level damage site was 
collected for immunoblotting experiment. In this experiment, we had three groups; 1) SCI 
only, 2) SCI + phenelzine (5mg/kg), and 3) SCI + hydralazine (5mg/kg). For the 
comparison, the same amount of hydralazine (5mg/kg) was also injected 2 times before 
collecting spinal cord tissue samples. 
 
Based on constructed acrolein standard curve in figure 3, we detected acrolein-
lysine adducts levels after SCI in SCI, SCI+phenelzine, and SCI+hydralazine groups. As 
figure 35 indicated, the acrolein-lysine adduct level in acrolein scavenger treatment 
groups was significantly lower than that in SCI only group (p<0.005). Specifically, the 
acrolein levels were 31.10 ± 4.21 in SCI only, 3.46 ± 1.98 in SCI + phenelzine injection 
group, and 8.70 ± 1.45 in SCI + hydralazine injection group. Especially, acrolein level in 
phenelzine injection group was statistically lower than that in hydralazine injection group 
(3.46 ± 1.98 in SCI + phenelzine injection vs. 8.70 ± 1.45 in SCI + hydralazine injection, 
p<0.05). This data supported that phenelzine could alleviate endogenous acrolein-lysine 
adduct level following SCI and it may provide more acrolein scavenging effects.  
 
In addition to immonoblotting, we also measured the acrolein metabolite 3-HPMA 
from urine with various dosages of acrolein scavengers in 1 day after SCI. In this study, 
we had 7 experiment groups; A: control, B: SCI post operative day (POD) 1, C: SCI 
POD1 + hydralazein (5mg/kg), D: SCI POD1 + hydralazine (25mg/kg), E: SCI 




POD1+phenelzine (60mg/kg). As figure 36 indicated, 3-HPMA level in SCI POD1 (B) 
was significantly higher than that in control (A) (3.51 ± 0.24 vs. 1.98 ± 0.21, p<0.05). 
The 3-HPMA levels in hydralazine treatment groups (C (5mg/kg) and D (25mg/kg)) 
showed that there were reductions of 3-HPMA levels in group C and D compared to SCI 
only group (B) (3.08 ± 0.22 in C vs. 3.51 ± 0.24 in B, p<0.05 and 2.22 ± 0.19 in D vs. 
3.51 ± 0.24 in B, p<0.01). The 3-HPMA levels in phenelzine injection groups were 2.84 
± 0.25 in E (phenelzine (5mg/kg)), 1.86 ± 0.13 in F (phenelzine (15mg/kg)), and 0.83 ± 
0.17 in G (phenelzine (60mg/kg)). All 3-HPMA levels in these groups were statistically 
lower than that in SCI POD1 group (B vs. E, p<0.05, B vs. F, p<0.01, B vs. G, p<0.005). 
In this result, there was no difference between C and E also there was statistically no 
difference between D and E. However, although there was no difference between D 
(hydralazine 25mg/kg) and E (phenelzine 5mg/kg), the 3-HPMA level in group E was as 
low as group D was. In addition, 3-HPMA level in group F (phenelzine 15mg/kg) was 
significantly lower than that in group D (hydralazine 25 mg/kg) (p<0.05). Taken these 
immunoblotting and 3-HPMA urine data together, phenelzine could be an effective 
























Figure 35. Reduction of Acrolein-lysine Adduct Level by Acrolein Scavengers  
 
Using immunoblotting, we measured the acrolein-lysine adduct levels from 1 day after 
SCI animals. Acrolein level were 31.10 ± 4.21 in SCI only, 3.46 ± 1.98 in SCI + 
phenelzine injection group, and 8.70 ± 1.45 in SCI + hydralazine injection group. 
Especially, acrolein level in phenelzine injection group was significantly lower than that 
in hydralazine injection group. N=4-6 in each group, ANOVA and Tukey tests for the 
statistical analysis. #p<0.05 when compared to hydralazine injection group and *p<0.01 













Figure 36. 3-HPMA Level in 1 Day after SCI with various Dosages of Acrolein 
Scavengers 
 
For the 3-HPMA measurement, we have 7 different groups. A: control, B: SCI post- 
operative day (POD)1, C: SCI POD1 + hydralazein (5mg/kg), D: SCI POD1 + 
hydralazine (25mg/kg), E: SCI POD1+phenelzine (5mg/kg), F: SCI POD1+phenelzine 
(15mg/kg), and G: SCI POD1+phenelzine (60mg/kg). All 3-HPMA levels in phenelzine 
injection groups were statistically lower than that in SCI POD1 group (B vs. E, p<0.05, B 
vs. F, p<0.01, B vs. G, p<0.005). In addition, 3-HPMA level in group F was significantly 
lower than that in group D (p<0.05). This data indicated that phenelzine might be a better 
acrolein scavenger compared to hydralazine. N= 4-6 in each group. ANOVA and Tukey 








5.4 Analgesic Effect of Phenelzine on Neuropathic Pain after SCI 
 
The benefit of phenelzine as an analgesic was investigated on SCI-induced 
neuropathic pain animal model. Initially, we created the moderate contused-SCI animal 
model by using NYU impactor. Based on 3-HPMA result, 15mg/kg of phenelzine was 
administrated for 2 weeks daily via systemically. For the comparison, hydralazine 
(5mg/kg) was injected for 2 weeks every day. Therefore, in this study, there were four 
different groups; 1) Sham control, 2) SCI only, 3) SCI + hydralazine (5mg/kg), and 4) 
SCI + phenelzine (15mg/kg). For the behavioral tests, we performed the mechanical and 
cold allodynia tests. For the experimental set up, we followed the materials and methods 
part in chapter 2 and chapter 3.  
 
Figure 37 showed mechanical threshold on various groups. Initially, the base lines 
were 15 grams in sham control, 14.23 ± 0.56 g in SCI only, 15g in SCI + phenelzine 
injection, and 15g in SCI + hydralazine injection group. However, from 2 weeks after 
treatment, mechanical threshold in acrolein-scavenger groups were significantly higher 
than that in SCI only group, which were lasted until the end of experiment periods. 
Specifically, mechanical threshold in phenelzine injection group was significantly higher 
than that in hydralazine treatment group 2 weeks after injection (14.44 ± 0.44g vs. 7.02 ± 
0.48g, p<0.005). This trends were maintained until 4 weeks (8.58 ± 0.42g vs. 6.55 ± 
0.76g in 3 weeks after injecting (p<0.05), and 8.27 ± 0.43g vs. 6.40 ± 0.66g 4 weeks after 
injecting (p<0.05)). During the test periods, there was no significant change in sham 
control group. Also, mechanical threshold in SCI only group showed consistently 
hypersensitive to mechanical stimulus during the test 2.48 ± 0.73g in 2 weeks, 2.55 ± 
0.48g in 3weeks, and 2.61 ± 0.78g in 4 weeks after SCI. This data indicated that acrolein 
scavenger phenelzine could attenuate the SCI-induced neuropathic pain mechanical 
allodynia and its efficacy was better than hydralazine’s.  
 
We also performed the cold allodynia test using 100% acetone. Similar to chapter 3, 




of hind limb and expressed it as withdrawal frequency to cold stimulus. Therefore, higher 
frequency means that animal was sensitive to acetone-generated cold effect. As indicated 
in figure 38, 2 weeks after SCI, neuropathic pain cold allodynia was well established on 
SCI animal group. In addition, during the whole experiment period, the withdrawal 
frequency in phenelzine and hydralaznie treatment groups was significantly lower than 
that in SCI only group. Especially, in 2 weeks, the frequency in phenelzine injection 
group was statistically lower than that in hydralaznie injection group (2.50 ± 0.56% vs. 
27.65 ± 5.94%, p<0.005). However, there was no difference between these groups during 
last of periods. This data also supported that phenelzine could alleviate the SCI-induced 
neuropathic pain cold allodynia after SCI, and although benefit of phenelzine was only 2 
weeks time point, phenelzine may provide better neuroprotective effects in the initial 




























Figure 37. Phenelzine Reduced the SCI-induced Mechanical Allodynia 
 
15mg/kg of phenelzine was injected into the SCI animals everyday for two weeks. The 
mechanical threshold was assessed by von Frey filaments up-down methods. As data 
indicated, mechanical thresholds in phenelzine and hydralazine injection were 
significantly higher than that in SCI only during the experiment periods. Especially, 
mechanical threshold in phenelzine injection group was higher than that in hydralazine 
injection group during the whole experiment periods. This data demonstrated that 
phenelzine could attenuated SCI-indiced neuropathic pain mechanical allodynia and its 
effect may be better than hydralazine. N=4-13 in each group, ANOVA and Tukey tests 
were used for statistical analysis. **p<0.005, *p<0.05 compared to SCI +HZ, #p<0.01 














Figure 38. Phenelzine Reduced SCI-induced Neuropathic Pain Cold Allodynia 
 
Withdrawal frequency to 100% acetone was assessed to investigate the effect of 
phenelzine on cold allodynia. For 2 weeks every day, 15mg/kg of phenelzine was 
injected into the SCI animal via I.P. During the experiment periods, frequency in acrolein 
scavengers treatment groups was lower than that of SCI only group. At 2 weeks after 
injection, phenelzine injection group showed the less sensitivity to cold stimulus than 
hydralazine injection group. This data indicated that phenelzine also could attenuate SCI-
induced cold allodynia. N=4-13 in each group, ANOVA and Tukey tests were used. 
**p<0.005 compared to phenelzine injection group, &p<0.001 compared to SCI only, 





5.5 Summary and Discussion 
 
Throughout this dissertation, we have used hydralazine as an acrolein-scavenger to 
alleviate acrolein-mediated neuronal damage, motor and sensory abnormalities following 
SCI. Hydralazine is the FDA-approved vasodilator. However, anti-hypertensive effect 
could be a life threatening side effect to SCI patients because of neurogenic shock. 
Therefore, with this information, someone might point out limitations of our studies 
(using hydralazine as an acrolein scavenger for neuroprotection after SCI). However, 
through the entire of these studies, the dosage of hydralazine was 5mg/kg, which was 
significantly lower than the suggested upper limitation for human patients with safe 
dosage, which is 7.5 mg/kg (Hamann and Shi, 2009). In addition, metabolite rate of 
rodents is much faster than that of human. Therefore, even though higher dosage of 
hydralazine could be metabolized very fast. This is supported by our data. In figure 36, 
we have injected 25mg/kg of hydralazine into group D for 3-HPMA detection. Even 
though the administered hydralazine (25mg/kg) was much higher than suggested upper 
limitation, we did not see any hypotensive side effect on SCI animals. However, although 
any hypotensive side effect by hydralazine has not been observed through this study, it is 
important to point out some limitations of hydralazine for clinical application.  
 
Fortunately, some research groups identified another acrolein scavenger phenezine 
which could alleviate acrolein-mediated cellular toxicity (Parent et al., 2002; Kaminskas 
et al., 2004b; Wood et al., 2006b). Phenelzine is a monoamine oxidase inhibitor which 
has a hydrazine functional group like hydralazine (Wood et al., 2006b). Therefore, 
phenelzine could be an acrolein-scavenger and, like hydralazine, it may react with 
acrolein 1:1 molecular ratio. However, compared to hydralazine, phenelzine could offer 
the some advantages. First, the half-life of phenelzine is much longer than that of 
hydralazin. Based on previous study, the half-life of phenelzine was 11.6 hours, which 
was much longer than half-life of hydralazine (30 min to 1 hour) (Reece, 1981). This 
aspect is very important, since oxidative stress and acrolein production contribute to the 




days, and weeks. Our data also supported this notation, through chapter 2, 3, and 4, we 
have demonstrated that acrolein-lysine adduct level was persisted at least 2 weeks after 
SCI (Due et al., 2014; Park et al., 2014). Therefore, with longer half-life of phenelzine, it 
may provide additional neuroprotective effect via acrolein scavenging after SCI. Second, 
phenelzine is not a vasodilator thus, it does not offer hypertensive side effect to SCI 
patients. Based on our data in figure 36, we injected 60mg/kg of phenelzine into the SCI 
animal and no anti-hypertensive effects were observed. In this sense, with phenelzine’s 
long half-life and non-hypertensive effect, phenelzine may offer additional 
neruoprotective role to the CNS following initial trauma. Lastly, phenelzine is the FDA-
approved anti-depressant. Therefore, it could bring additional benefits to SCI patients 
who are suffering from chronic neuropathic pain and post traumatic stress after SCI.  
 
The benefits of phenelzine were further supported by previous in vitro data. Based 
on in vitro tests, acrolein scavenging effects of phenelzin were very similar to 
hydralazine’s with concentration dependent way. Acrolein-treated cell viability test with 
various acrolein scavengers such as phenelzine and hydralazine indicated that the 
phenelzine had an ability to protect against acrolein-mediated cell death, which was 
statistically no different from hydralazine treatment group. In addition, cell viability was 
also improved in uninjured cells by treating phenelzine, since it could remove the 
endogenous acrolein produced by PC12 cell, and also the free radicals such as DPPH 
which were produced by normal cells.  
 
In addition to the in vitro results, the benefits of phenelzine as an acrolein 
scavenger were supported by our in vivo SCI animal study. The immunoblotting and 
urine 3-HPMA data results demonstrated that phenelzine could result in the reduction of 
acrolein levels after SCI (Figures 35 and 36). Especially, these data showed that 
phenelzine could be a better acrolein scavenger than hydralazine is, since the acrolein-
lysine adduct level in phenelzine group was significantly lower than that in hydralazine. 
In addition, although there was no different of 3-HPMA levels between 25mg/kg of 





5 mg/kg of phenelzine injection group was as low as 25mg/kg of hydralazine injection 
group was. Furthermore, the 3-HPMA level in 15mg/kg of phenelzine injection group 
was significantly lower than that in 25mg/kg of hydralazine’s.  
 
The benefits of phenelzine on sensory neurons’ abnormalities following SCI were 
investigated using mechanical and cold allodynia. The mechanical allodynia data (Figure 
37) indicated that phenelzine also could attenuate the hypersensitivity to mechanical 
stimulus. Especially, mechanical threshold in phenelzine injection group was similar to 
that in sham control, and statistically higher than hydralazine’s during the experiment 
period. Withdrawal frequency to cold stimulus data (Figure 38) also demonstrated the 
analgesic benefits of phenelzine after SCI. Especially, at 2 weeks after SCI, the frequency 
of phenelzine injection group was lower than that of hydralazine. Taken these results 
together, with its long half-life and non-hypotension effects, phenelzine could be used an 
acrolein scavenger with high dosage as an alternative to hydralazine. However, 
phenelzine has been implicated in a wide range of side effects such as urinary retention, 
muscle tremors, food restriction, and drug interaction (Verrilli et al., 1987; Stonnington et 
al., 1988; Song et al., 2010). Therefore, additional research for phenelzine should be 
performed. In addition, the developing novel drug delivery system also should be 













CHAPTER 6. THE EFFECT OF POTASSIUM CHANNEL BLOCKER ON SCI-
INDUCED MOTOR DEFICIT AND NEUROPATHIC PAIN  
6.1 Background and Research Scope of This Study 
 
Traumatic SCI causes myelin damage mainly in white matter, which contribute to 
expose the past potassium channels at the juxtaparanodal regions (Shi and Blight, 1996, 
1997; Leung et al., 2011a). Under normal physiological condition, juxtaparanodal regions 
are covered by myelin, which prevent from potassium ions leaking and allow it to 
depolarize to generate action potential (Chiu and Ritchie, 1980; Haghighi et al., 1995; 
Sun et al., 2010; Leung et al., 2011a). Since the type of SCI is most likely contused 
and/or compressed injury (Blight, 1983; Blight and Decrescito, 1986; Hayes et al., 1993; 
Kakulas, 1999), myelin damage in white matter of spinal cord leads to the potassium 
efflux and causes the action potential failure. Furthermore, acrolein generation resulting 
from inflammation has been known to play a critical role in demyelination after neuronal 
damage (Smith et al., 1999; Gilgun-Sherki et al., 2004). In this sense, blocking the 
potassium channels could be an effective way to re-generate action potential after SCI 
(Waxman, 1989; Blight, 1991; Shi and Blight, 1997).  
 
4-aminopyridine (4-AP) has been identified as a fast potassium channel blocker, 
which could restore axonal conduction after SCI (Blight and Decrescito, 1986; Haghighi 
et al., 1995). The effect of 4-AP as an effective potassium channel blocker was supported 
by recent approval by the FDA for promoting motor dysfunction in multiple sclerosis 
(MS) via restoring axonal action potential. However, there are some limitations of using 




seizures (Stork and Hoffman, 1994; Potter et al., 1998; Pena and Tapia, 1999; Korenke et 
al., 2008). In this sense, a developing an alternative potassium channel blocker to 4-AP is 
required.  
 
Our lab has been focusing on a new type of fast potassium channel blocker 4-
aminopyridine-3-methanol (4-AP-3-MeOH). Many of previous researches have been 
shown that this compound could block potassium channels and restore axonal conduction 
to similar level of normal axonal conduction in various neurodegenerative disease models 
such as MS, and SCI where the myelin damage is occurred (Sun et al., 2010; Leung et al., 
2011a). Furthermore, the effective lowest concentration of 4AP-3MeOH for 
mechanically injured spinal cord is between 0.01 and 0.1 μM, which is significantly 
lower than that of 4-AP (between 0.1 and 1 μM) (Shi and Blight, 1997; Sun et al., 2010). 
However, the effects of 4-AP and 4AP-3MeOH have not been investigated in SCI and 
SCI-induced neuropathic pain animal model. Therefore, in the current study, we test 
whether potassium channel blockers can enhance the SCI-induced motor function deficits, 
and attenuate SCI-induced neuropathic pain.  
 
6.2 The Effects of Potassium Channel Blockers on Neuropathic Pain 
 
Initially, we have tested the effect of potassium channel blockers such as 4-AP and 
4AP-3MeOH on SCI-induced neuropathic pain model. We generated contused-SCI 
model by using NYU impactor. Two weeks after SCI, two different types of potassium 
channel blockers were used for this study; 4-AP and 4AP-3MeOH injection groups. 
Based on the previous study (Sun et al., 2010), since the effect of potassium channel 
blockers is transient, we performed mechanical and cold allodynia tests every one hour 
after injection until 6 hours, and did the same tests at 24 hours after injection. The same 
amount (1mg/kg) of potassium channel blockers (4-AP and 4AP-3MeOH) was injected 





Figure 39 showed the mechanical threshold on the various groups. Before injection, 
the mechanical thresholds in 4-AP, 4AP-3MeOH, and SCI were 2.99 ± 0.51g, 2.67 ± 
0.44g, and 2.47 ± 0.14g respectively. However, from at 2 hours after injection to at 5 
hours after injection, the mechanical threshold in potassium channel blocker injection 
groups were significantly higher than that in SCI only group. Especially, at 3 hours after 
injection, mechanical threshold in 4AP-3MeOH was 7.41 ± 0.51g, which was statistically 
higher than that in 4-AP group (4.98 ± 0.61g, p<0.01). The significant differences 
between 4-AP and 4AP-3MeOH were maintained by 5 hours after injection (7.23 ± 0.73g 
vs. 4.45 ± 0.22g at 4 hours after injection, p<0.01, and 5.65 ± 0.44g vs. 3.51 ± 0.30g at 5 
hours after injection, p<0.01). This data showed that potassium channel blocker could 
attenuate neuropathic pain mechanical allodynia after SCI, and the analgesic effect of 
4AP-3MeOH may be better than 4-AP’s. However, the mechanical threshold in whole 
groups got closer to their initial values, which indicated that the effect of potassium 
channel blocker was transient.  
 
Withdrawal frequency to cold stimulus is shown in figure 40. The base lines of 
withdrawal frequency were 52.50 ± 4.78% in 4-AP injection group, 50.00 ± 3.13% in 
4AP-3MeOH injection group, and 55.50 ± 3.53% respectively, while 7.21 ± 3.21% in 
uninjured control group. Very similar to mechanical allodynia, potassium channel 
blockers could alleviate withdrawal frequency to 100% acetone stimulus from at 1 hour 
after injection to at 4 hours after injection. In addition, the efficacy of 4AP-3MeOH, in 
terms of analgesic, was further supported by this data. Specifically, at 1 hour after 
injection, frequency in 4AP-3MeOH injection group was 14.51 ± 4.33%, while in 4-AP 
injection group, 35.00 ± 2.89% (p<0.01). (At 2 hours after injection, 15.50 ± 2.33% vs. 
27.50 ± 2.89% (p<0.01), at 3 hours after injection, 20.50 ± 4.33% vs. 32.50 ± 2.55% 
(p<0.01), and at 4 hours after injection, 30.50 ± 2.21% vs. 42.50 ± 2.55% (p<0.01)). 
Again, very similar to mechanical threshold, after 24 hours injection, cold allodynia 
closed to base line except 4AP-3MeOH, which showed a lower frequency compared to 4-





could reduce SCI-induced cold allodynia, and 4AP-3MeOH might have better analgesic 














Figure 39. Potassium Channel Blockers Reduced Mechanical Allodynia after SCI 
 
1mg/kg of 4-AP and 4AP-3MeOH were injected systemically 2 weeks after SCI. To test 
the mechanical threshold, we performed von Frey filaments test. The data showed that 
two different types of potassium channel blockers could reduce the mechanical threshold 
from 2 hours to 5 hours after injection, but its effect was not maintained beyond 24 hours 
after injection except 4AP-3MeOH injection group. N=6-8 in each group. ANOVA and 
Tukey tests were used for statistical analysis. **p<0.01 compared to 4-AP injection 

















Figure 40. Potassium Channel Blockers Reduced Cold Allodynia after SCI 
 
To investigate the effect of potassium channel blockers on cold allodynia after SCI, we 
applied 100% acetone onto the animals’ hind limb plantar surface. Very similar to 
mechanical threshold, potassium channel blockers reduced the withdrawal frequency to 
acetone during some time points (from at 1 hour to at 4 hours after injection). Still, 24 
hours after injection, 4AP-3MeOH injection group showed less sensitivity to cold 
stimulus compared to 4-AP injection group. N=6-8 in each group, ANOVA and Tukey 
tests were used for analysis. *p<0.05, **p<0.01 compared to 4-AP injection group, 









6.3 The Effect of Potassium Channel Blockers on Motor Function Deficits 
 
To investigate the effect of potassium channel blockers on motor function recovery 
after SCI, we administered 2 different dosages of 4AP-3MeOH (1mg/kg and 5mg/kg) and 
1mg/kg of 4-AP 2 weeks after SCI. Then, 30min after injection, we performed the 
rotarod tests. Rotarod test is commonly used for investigation of motor function 
coordination to evaluate the effect of medication on neurogenerative diseases. Previous 
study showed that gradually increased rotation speed resulted in the greater sensitivity of 
the test (Jones and Roberts, 1968). Therefore, the rotation speed was gradually increased 
by 3 rotations per minute (RPM) every 10 s until it reached 30 RPM and 180 s. Before 
SCI, all the animals have passed this training, and we did not use the animals that did not 
pass the training. When the animals completely fall off from the device, or spin around 
twice on the device, we stopped the test and recorded the RPM and time on the rotarod. 
These values indicated the animal’s capability of remaining on the spinning rod and 
motor function recovery by injected medication.  
 
Figure 41 showed the time on rotarod of 5 different groups; normal control (A), 
SCI only (B), 5mg/kg of 4AP-3MeOH (C), 1mg/kg of 4AP-3MeOH (D), and 1mg/kg of 
4-AP (E). There were no significant differences between SCI only and 1mg/kg of 4-AP 
and 4AP-3MeOH groups (47.30 ± 3.69 sec. in SCI, 46.33 ± 2.01 sec. in 1mg/kg of 4AP-
3MeOH, and 45.55 ± 2.84 sec. in 1mg/kg of 4-AP). However, when we treated 5mg/kg 
of 4AP-3MeOH, the time on rotarod was significantly longer than any other groups. We 
did not investigate the effect of 5mg/kg of 4-AP on motor function recovery, since the 
animals showed the seizure-like activity after injection. We also checked the rotation per 
minutes (RPM) at the same time. As figure 42 indicated, there were no differences 
between potassium channel blocker injection groups and SCI only group. Specifically, 
the RPM in SCI only group was 9.68 ± 0.51 RPM, 9.58 ± 0.48 RPM in 1mg/kg of 4AP-
3MeOH, and 9.47 ± 0.39 RPM in 1mg/kg of 4-AP. However, the RPM in 5mg/kg of 
4AP-3MeOH showed 9.58 ± 0.48 RPM, which was statistically different compared to 




the motor function after SCI, and high level of 4AP-3MeOH could be used safely 






































Figure 41. The Effect of Potassium Channel Blocker on Motor Deficit after SCI 
 
To assess the effect of potassium channel blockers on motor function, two differences 
dosages of 4AP-3MeOH (1mg/kg and 5mg/kg), and 1mg/kg of 4-AP were injected 
systemically (A: normal control, B: SCI only, C: 4AP-3MeOH (5mg/kg), D: 4AP-
3MeOH (1mg/kg), and E: 4-AP (1mg/kg)). The time on device in 5mg/kg of 4AP-
3MeOH was longer than any other groups. This data showed the high level of 4AP-
3MeOH could promote motor function after SCI. N=6-8 in each group. ANOVA and 
















Figure 42. Potassium Channel Blockers Promoted the Motor Recovery after SCI. 
 
The animals’ motor function recovery after SCI was assessed by measuring the rotation 
per minute on the rotarod (A: normal control, B: SCI only, C: 4AP-3MeOH (5mg/kg), D: 
4AP-3MeOH (1mg/kg), and E: 4-AP (1mg/kg)). Similar to time on the rotarod, RPM in 
5mg/kg of 4AP-3MeOH was higher than any other groups. N= 6-8 in each group, 











6.4 Summary and Discussion 
 
Through this study, we have demonstrated that potassium channels blockers could 
attenuate SCI-induced neuropathic pain behaviors (figures 39 and 40). Especially, in 
terms of analgesic, the effect of 4AP-3MeOH was better than that of 4-AP. In addition, 
although there were no difference between SCI only and treatment groups under the same 
dosage of potassium channel blockers, higher dosage of 4AP-3MeOH (5mg/kg) was 
effective to improve the motor function after SCI (figures 41 and 42). These behavior 
tests demonstrated that potassium channel blockers could not only attenuate neuropathic 
pain behaviors, but promote motor function recovery after SCI. This notion is further 
supported by previous studies (Van Diemen et al., 1993; Wu et al., 2009). Furthermore, 
this data showed that the efficacy and therapeutic value of 4AP-3MeOH. Even though we 
did not present the data, 5mg/kg of 4AP-3MeOH also led to attenuation of neuropathic 
pain mechanical and cold allodynia, and its efficacy was better than 1mg/kg of 4AP-
3MeOH’s. It was unable to test with 5mg/kg of 4-AP, since the animals showed the 
seizure-like activity after injection, but this action went away in 2 hours after injection 
because of the transient property of potassium channel blocks (Sun et al., 2010). 
Furthermore, high dosage of 4AP-3MeOH (5mg/kg) also led to better results compared to 
1mg/kg of 4AP-3MeOH and 4-AP. These data supported that 4AP-3MeOH could be used 
as an effective potassium channel blocker with high dosage.  
 
Two major differences between 4AP-3MeOH and 4-AP led to different results in 
this experiment. First of all, the effective lowest concentration of 4AP-3MeOH (between 
0.01 and 0.1 μM) to recover axonal action potential is significantly lower than that of 4-
AP (between 0.1 and 1 μM) (Shi and Blight, 1997; Sun et al., 2010). Secondly, based on 
the ex vivo studies, when they treated with 4AP-3MeOH, axon can restore its action 
potentials, which was similar to axons’ action potentials way under normal condition 
(Jensen and Shi, 2003; Sun et al., 2010). In addition, 4AP-3MeOH can also significantly 





on these mechanisms, high dosage of 4AP-3MeOH may induce the motor function 
recovery after SCI.  
 
The hyperexcitability of primary afferent neuron after SCI results in neuropathic 
pain allodynia. Although many of voltage-gated channels are implicated in transmission 
of noxious stimuli to higher order of neuron and hyperexcitability, potassium channels 
play an important role in transmission of pain information by regulating membrane 
potential and generating action potential. In addition, neuronal damage leads to the 
opening of potassium channels, which results in hyperpolarization of cell membrane 
(Ficker and Heinemann, 1992; Wu and Saggau, 1997; Takeda et al., 2011). Therefore, 
potassium channels have been focused on as a therapeutic target for neuropathic pain 
treatment after neuronal damage. This notion is well supported by our data (figures 39 
and 40). These data indicated that potassium channel blockers could attenuate 
neuropathic pain mechanical and cold allodynia following SCI. Specifically, analgesic 
effect of 4AP-3MeOH was better than that of 4-AP. Taken together, based on these data 
using SCI-induced neuropathic pain animal model, potassium channel blockers can not 
only alleviate neuropathic pain, but promote motor function recovery following SCI. 
Especially, 4AP-3MeOH may be an effective potassium channel blocker as an alternative 
to 4-AP in enhancing the sensory and motor dysfunction recovery after neuronal damage. 
However, the working mechanisms of potassium channel blockers on the sensory neuron 











CHAPTER 7. SUMMARY AND CONCLUSION 
Traumatic spinal cord injury (SCI) induces motor and sensory dysfunction, 
bladder reflexive dysfunction, urinary tract infection, renal malfunction, loss of 
respiratory function, loss of sexual function, and pneumonia. Beyond these SCI-induced 
malfunctions, neuropathic pain after SCI has significant negative effects on patients’ 
quality of life. In spite of research to improve and recover functional deficits after SCI, 
insufficient therapeutic targets lead to a frustrating condition to treat. Recently, 
antioxidants have attracted researchers’ attention to alleviate the SCI-induced 
malfunctions. However, recent clinical trials using these medications have failed to 
improve functional recovery after SCI. Despite of failing the clinical trials, this study 
indicated that attenuating oxidative stress by targeting a neurotoxin, acrolein, could be an 
effective way to improve the SCI-induced dysfunctions. 
 
As the strongest electrophile and the most reactive aldehydes, acrolein has been 
implicated in various neurodegenerative diseases (Hensley et al., 2000; Vincent et al., 
2002; Naoi et al., 2005; Liu-Snyder et al., 2006b; Schwartz et al., 2008). Acrolein can 
originate through exogenously through environmental sources such as air pollution and 
cigarette smoke, and endogenously through the breakdown of carbohydrates and amino 
acids (Witz, 1989; Ghilarducci and Tjeerdema, 1995; Hamann et al., 2008b). In addition 
to its high reactivity, the half-life of acrolein is much longer than that of the other ROS. 
Acrolein can bind to protein and DNA, forming acrolein-protein adducts, which have 
half-lives that are even longer than that of free acrolein. Furthermore, acrolein can bind to 
endogenous anti-oxidant GSH and react with it much faster than other types of oxidative 
stress-inducing molecules. With these unique properties, acrolein can induce the vicious 




Because acrolein plays an important role in pathogenesis after traumatic SCI, we 
have focused on acrolein scavenging as the most important means of intervention to 
further degeneration after SCI. The FDA-approved hypertensive medication hydralazine 
has shown its acrolein-scavenging effect with the hydrazine functional group (Burcham 
et al., 2000; Burcham et al., 2002; Burcham et al., 2004). In addition, because hydralazine 
can react with free acrolein and acrolein-protein adducts in an equimolar manner, 
equimolar concentration of hydralazine can neutralize acrolein entirely (Burcham et al., 
2002; Burcham et al., 2004; Hamann et al., 2008a; Hamann and Shi, 2009). Many 
previous studies have showed acrolein-scavenging effects of hydralazine via in vitro tests 
(Liu and Wood; Burcham and Pyke, 2006; Liu-Snyder et al., 2006b). However, to our 
knowledge, this is the first study that hydralazine has been shown to reduce the acrolein 
levels and acrolein-induced neuropathic pain through in vivo animal SCI models.  
 
The main goals of chapter 2 were to ascertain the pathological role of acrolein in 
the CNS, and the effects of acrolein scavenging via hydralazine in an in vivo SCI animal 
model. Therefore, we hypothesized, first, the level of acrolein would depend on the SCI 
severity, second, suppressing acrolein would reduce the neuronal damage and promote 
functional recovery, and third, acrolein itself would generate the neurological deficits. 
Figures 7 indicated that the elevations of acrolein levels were correlated with SCI 
severity. Specifically, the elevated level of acrolein persisted for at least two weeks after 
both moderate and severe SCI groups. This was further supported by urine 3-HPMA 
results (Figure 8). With a recently developed technique, LC/MS/MS, we measured the 
concentration of the acrolein metabolite, 3-HPMA, in animals’ urine samples, of which 
levels were also correlated with SCI severity. Before testing the benefits of acrolein 
scavenging by hydralazine, we investigated whether it could reach the therapeutic level 
within the CNS. Figure 9 showed that systemically injected hydralazine was detected in 
concentrations higher than the minimal level needed to reduce acrolein-mediated damage. 
With this information, we injected 5 mg/kg of hydralazine after SCI, and figures 10 and 
11 showed that hydralazine could reduce the acrolein level. In addition to reducing 




the neuronal tissue damage, but also improve locomotor functional recovery after SCI 
(Figures 12 and 13). These results may support that elevated acrolein after SCI lead to 
neuronal tissue damage and motor dysfunction, and by scavenging acrolein through 
hydralazine, we can attenuate the generation of cysts formation and malfunction of motor 
neuron. This notion is again supported by figure 15. In this data, micro-injected acrolein 
into the spinal cord induced the neuronal tissue damage and motor function deficits 
without any traumatic injury. Through this study, we showed that, first, acrolein level is 
correlated with SCI severity, second, systemic application of hydralazine can reduce 
acrolein levels, neuronal damage, and promote motor function recovery, and third, 
considering the role of acrolein after SCI, anti-acrolein therapy could be an effective 
treatment to improve motor dysfunction and neuronal damage. 
 
As a TRPA1 channel specific agonist and an inflammatory factor, acrolein plays 
an important role in neuropathic pain pathogenesis after SCI. In chapter 2, figure 14, 
showed that persistent acrolein level elevation was correlated with the onset and 
establishment of neuropathic pain after SCI. In addition to increased levels of acrolein for 
two weeks after SCI (figure 16), we demonstrated that the TRPA1 gene expression level 
was up-regulated in various tissues such as dorsal horn of spinal cord, DRGs, and hind-
limb paw skin one week and two weeks after SCI (figures 17 and 25). In addition, figures 
14 and 22 showed that there was an increase in sensitivity in mechanical and cold stimuli 
after SCI, furthermore, micro-injected acrolein resulted in neuropathic pain-like 
mechanical and cold allodynia behaviors without any traumatic injury to the spinal cord 
(figures 21 and 30). Acrolein-induced neuropathic pain generation was further supported 
by up-regulation of gene expression level of TRPA1 (figure 29). However, as figures 26 
and 27 indicated, hydralazine could down-regulate the TRPA1 gene expression level one 
and two weeks after SCI in various tissues such as dorsal horn, DRG and paw skin. 
Therefore, the DRG neurons may remain hypersensitive to its effects because of acrolein-





Electrophysiological data demonstrated the effects of acrolein and SCI on cellular 
hypersensitivity. As figure 18 indicated, acrolein could increase the intracellular calcium 
levels after SCI and there was an increased in number of cells that responded to acrolein 
after SCI. Furthermore, SCI alone could increase the excitability of nociceptors (small 
and medium diameter of sensory neurons). In figure 19, we investigated the magnitude of 
current thresholds to generate the single action potentials, and the data showed that SCI 
could decrease the current threshold on sensory neurons. In addition, acrolein could 
increase the number of action potentials on sham and SCI groups (figure 20) and 
acrolein-mediated cellular excitability was enhanced after SCI. This notion is also 
supported by figure 33. Intradermally injected acrolein could increase the mechanical 
sensitivity to von Frey filaments in the sham control group, but acrolein-mediated 
mechanical sensitivity was enhanced in SCI group.  
 
Taken together, these data showed that acrolein could increase neuronal 
sensitization, and its effect could be enhanced after SCI. In addition, considering the 
persisted elevation of acrolein for two weeks and the onset of neuropathic pain after SCI, 
acrolein could be a valuable therapeutic target for neuropathic pain. Therefore, 
scavenging acrolein by hydralazine may be an effective way to reduce not only acute 
neuropathic pain, but also chronic stages of neuropathic pain after SCI (figure 23). 
 
With the anti-hypertensive property of hydralazine, it has number of limitations 
for the SCI patients. The major drawback of hydralazine is hypotensive effect to SCI 
patients, which could be a life threatening side effect because it could lead to neurogenic 
shock. In addition, with its short half-life, it has to be administrated more frequently for 
the neuro-protection. Recently, a monoamine oxidase inhibitor, phenelzine, was 
identified as a possible acrolein scavenger. Since it has a hydrazine functional group like 
hydralazine, it is reasonable to anticipate that it may react with acrolein 1:1 molecular 
ratio. However, Reece and colleagues showed that the half-life of phenelzine (11.6 hours) 
was significantly longer than that of hydralazine (Reece, 1981). Normally, secondary 




cord after primary injury were observed in the hours to days after injury. Therefore, 
phenelzine’s long half-life property may inhibit acrolein-mediated additional damage 
after primary injury. Furthermore, as the FDA-approved anti-depressant and non-
hypertensive medication, phenelzine could be used with a higher dosage without severe 
side effects (figure 36), and provide additional neuroprotective role for the treatment of 
SCI-induced neuropathic pain behaviors (figures 37 and 38).  
 
Based on previous studies, most SCIs are contused and/or compressed injury, 
which causes myelin damage mainly in white matter leading to exposure of potassium 
channels at the juxtaparanodal regions (Blight, 1983; Blight and Decrescito, 1986; Hayes 
et al., 1993; Leung et al., 2011a). Efflux of potassium ions results in slowing or the 
complete blocking of axonal conduction. Potassium channels play an important role in 
transmission of noxious stimuli to the higher order of neuron by regulating membrane 
potential and generating action potential. Therefore, many of researchers have focused on 
potassium channels as a potential therapeutic target for neuropathic pain after neuronal 
damage. So, initially, we tested if potassium channel blockers (4-AP and 4AP-3MeOH) 
could attenuate neuropathic pain mechanical and cold allodynia after SCI. As figures 39 
and 40 indicated, both potassium channel blockers could reduce neuropathic pain 
behaviors, but the analgesic effect of 4AP-3MeOH was better compared to 4AP. We also 
checked the benefits of potassium channel blockers on the motor function deficits after 
SCI. Even though 1mg/kg of 4AP and 4AP-3MeOH did not show any effect on motor 
function recovery, a higher dosage of 5 mg/kg of 4AP-3MeOH did indeed show motor 
function improvement after SCI (figures 41 and 42). Taken together, potassium channel 
blockers could not only attenuate the neuropathic pain behavior, but also improve the 
motor function recovery after SCI. However, as we have already mentioned above, 
5mg/kg of 4-AP induced the seizure-like behavior on animals, even though this activity 
did not last more than 2 hours because of its transient property. So, when we consider the 
efficacy and safety, 4AP-3MeOH would provide additional advantages to improve motor 
and sensory dysfunctions. For the future, we need to investigate various factors that could 





disease patients. In addition, we also need to investigate the working mechanisms of 




CHAPTER 8. FUTURE STUDIES 
We have demonstrated the potential and pathophysiological values of acrolein as 
a therapeutic target for SCI-induced neuropathic pain. Our data supported that acrolein 
scavengers may be a novel analgesic to intervene neuropathic pain after SCI.  
 
In particular, the immunoblotting and urine 3-HPMA results showed that 
elevation of acrolein level correlated with SCI severity and, based on the immunoblotting 
result, its level could be persisted at least two weeks after SCI. In addition, systemic 
application of acrolein scavengers, hydralazine and phenelzine, could decrease 
accumulation of acrolein-lysine adducts and 3-HPMA levels following contusion SCI. 
Although we have shown the elevation of acrolein level after SCI, it has been uncertain 
what types of cells produce and accumulate acrolein after neuronal damage. Many studies 
have demonstrated the accumulation of acrolein-protein adducts through 
immunohistochemistry (Luo et al., 2007; Ismahil et al., 2011). However, additional 
studies should be performed to investigate where acrolein is produced and accumulated. 
For this, we may use specific markers such as GFAP for astrocyte, DAPI for nuclei, and 
MBP (myelin basic protein) for myelin. This experiment would provide additional 
information about the exact location where the acrolein-protein adducts is formed. This 
information could be utilized to develop the efficient acrolein scavengers as well.  
 
Neuropathic pain data showed that, as a pro-nociceptive factor, SCI-induced 
formation of acrolein correlated with the onset of neuropathic pain behaviors. This is 
supported through reduction of pain behaviors by using acrolein scavengers, such as 
hydralazine and phenelzine, after SCI. Furthermore, electrophysiology data indicated that 
acrolein could enhance the sensory neuron’s excitability after SCI and even sensory 
neuronal cells from sham control group. This phenomenon could be explained by our 
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gene expression data. The data showed that the elevation and maintenance of DRG 
sensory neurons’ excitability may be mediated by up-regulation of TRPA1 gene 
expression level, which is also correlated with elevation of acrolein level after SCI. An 
increase in TRPA1 gene expression level persisted for at least two weeks after SCI and 
its levels were decreased by scavenging the SCI-induced acrolein via hydralazine. 
Therefore, targeting acrolein for an analgesic effect would be a promising approach to 
attenuate neuropathic pain behaviors after SCI. However, we cannot rule out the 
possibility that generation of neuropathic pain by other acrolein-mediated pathways. As 
we already mentioned through this study, acrolein is known as pro-inflammatory factor. 
Based on previous studies, acrolein has been shown to stimulate the release of 
chemokines such as monocyte chemotactic protein-1 (MCP-1 or CCL2) after SCI 
(Knerlich-Lukoschus et al., 2010; Knerlich-Lukoschus et al., 2011b). In DRG, MCP-1 is 
expressed in small and medium diameter of sensory neurons which are also colocalized 
extensively with TRPA1 channels (Abbadie, 2005). In addition, MCP-1 is released at the 
spinal dorsal horn to modulate the activity of post synaptic neurons and glial cells, which 
express the MCP-1 specific receptor CCR-2 (White et al., 2009). A recent study showed 
that the activation of CCR-2 by MCP-1, which was activated by acrolein, could elicit 
membrane depolarization, trigger action potentials and sensitize nociceptors through the 
transactivation of TRPA1 channels to generate neuropathic pain after injury (Knerlich-
Lukoschus et al., 2010). In this sense, based on reactive nature of acrolein, coupled with 
its diffusive, stable, and prolonged presence in the body, acrolein would play an 
important role in an inflammation-associated pathway that leads to the chronic nature of 
neuropathic pain. Therefore, the exact mechanisms and involvement of acrolein on the 
immune response-mediated generation of neuropathic pain after SCI should be performed. 
In line with immune system-evoked neuropathic pain, we also have to further investigate 
the balance between neuropathic pain generation and neuro-inflammatory response after 
injury. Under the normal physiological condition chemokines usually have positive 
effects on limitation of cellular and tissue damage, and they are well controlled by a 
complex network. However under neuronal damage conditions, this complex mechanism 
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is also damaged, and is insufficient to control inflammation. Therefore, the inflammatory 
response itself could result in a various range of chronic neuronal diseases including 
neuropathic pain after SCI. So, further studies are needed to demonstrate the mechanisms 
keeping a balance between neuro-inflammation and chronic neuronal diseases such as 
neuropathic pain.  
 
As a non-selective cation channel, TRPA1 channels play an important role in 
transmitting pain signaling to higher order neurons. Based on our preliminary data, it is 
well known that electrophilic reactive compounds such as acrolein can activate TRPA1 
channel after SCI. In addition, we have demonstrated that acrolein itself could increase 
the excitability of DRG sensory neuron, which is enhanced after SCI. Furthermore, our 
data indicated that SCI itself could affect the overall activity of sensory neurons’ 
sensitivity in nociceptor neurons (c and Aδ primary afferent neurons). Together with 
immunodotblotting results, our data demonstrated that formation of acrolein after SCI 
was correlated with the enhancement of neuronal sensitization and elevation of TRPA1 
gene expression level after SCI. As we have already mentioned in chapter 1, many of 
research articles demonstrated the various mechanisms about the activation of TRPA1 
channels after tissue damages. However, it is still unclear how this channel is deactivated. 
Additionally, we still do not know the exact downstream biochemical signaling pathway 
of the channel for subsequent activation after deactivation. Therefore, the logical next 
study would be to investigate the mechanisms of TRPA1 desensitization after its 
activation. Based on previous studies (Nilius et al.; Bandell et al., 2007), the binding 
between acrolein and cysteine residues by Michael addition is reversible, while the other 
covalent modifications are not. This property could be a key mechanism for re-activation 
after deactivation of TRPA1 channel and vice versa. Therefore, initially, we should focus 
on reversible reactions between the TRPA1 channel and its agonists.  
 
As an additional approach to the TRPA1 channel desensitization study, we also 
should check the effect and role of TRPA1 channel specific antagonists, such as HC-
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030031. Based on previous studies, oral administration of HC-030031 exhibited a 
significant decrease in neuropathic pain-like behavior in inflammatory and neuropathic 
pain animal models compared to TRPA1 antagonist non-treatment group (Eid et al., 
2008). This study showed the potential analgesic effect of TRPA1 specific antagonist on 
neuropathic pain model. However, possible working mechanisms of non-electrophilic 
TRPA1 channel antagonists, such as HC-030031, have not been investigated. In addition, 
some research articles have shown that some electrophilic TRPA1 antagonist compounds, 
such as AP-18 and A-967079, can act as both an agonists and antagonists depending on 
their concentration (Garcia-Anoveros and Nagata, 2007; Chen et al., 2011). Therefore, 
without exact working mechanisms of TRPA1 antagonists, the potential value of TRPA1 
antagonists as therapeutic agents remains uncertain. Thus, we need to investigate the 
mechanisms and optimal working concentrations of various TRPA1 specific antagonists, 
either electrophilic or non-electrophilic, through in vitro tests and in vivo disease animal 
models.  
 
Although several unique properties of the TRPA1 channel make it an attractive 
potential therapeutic target to treat neuropathic pain after injury, there are potential 
disadvantages using TRPA1 channel for treatment. First of all, because of the wide 
spread presence of TRPA1 channel in various tissues, such as bladder, skin cell, GI track, 
nervous system, and respiratory track, there could be unwanted side effects when we use 
TRPA1 channel-specific medications. Second, the level of correlation between human 
TRPA1 and rodents TRPA1 is only 79%. Therefore, pre-clinical experimental results 
with TRPA1 antagonists or agonists in rodent model would not act in the same way in the 
human. In this sense, although the amino acid sequences in the N-terminal of TRPA1 or 
in the EF-hand domain share some similarities, the critical amino acid such as cysteine 
and lysine in the N-terminal differ between species. This difference could lead to 
changing in the affinity of the agonists or antagonists to the TRPA1 channel. To 
overcome this barrier, using a transgenic animal model which expresses the human 
TRPA1 channel could be an effective way to reduce such discrepancies. In addition, by 
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using this model, pre-clinical experiments can provide valuable information for 
developing effective analgesic compounds.  
 
One of the challenging problems of pharmacological treatment is the delivery of 
compound to specific cell types. As we already mentioned above, the wide spread of 
expression of TRPA1 channel in nociceptors makes it an excellent candidate for 
therapeutic target. As a non-selective cation channel, TRPA1 channel’s pore size is 
stimulus- and time- dependent. This feature of the TRPA1 channel can be utilized to 
increase the entry of small membrane-impermeable cationic compounds into the target 
sensory neuron to block the pain transmission. To accomplish this aim, we may 
encapsulate therapeutic compounds in a drug delivery vehicle. By using a drug delivery 
vehicle, we can not only improve a compound’s specificity for targeted cells, but prevent 
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